Oncoletter
Navigation überspringen
  • Kongressberichte 2021
    • 63rd ASH Annual Meeting and Exposition In-Person/Virtual
      • Late-Breaking Abstracts Session
      • Highlights of the Conference: Statements & Opinions
      • Press Briefing
        • COVID-19 Takes a Toll on People with Blood Cancers and Disorders
        • Studies Highlight Novel Approaches to Screening for and Treating Blood Disorders
      • ALL
        • Clinical and Epidemiological: Clinical, genetic and societal
        • Therapies, Excluding Transplantation and Cellular Immunotherapies I
        • Therapies, Excluding Transplantation and Cellular Immunotherapies II
      • AML
        • Acute Myeloid Leukemia: Clinical and Epidemiological
          • COVID and beyond
          • Outcomes and Omics Potpourri
          • Practice-changing studies
        • Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies
          • Innovative induction regimens in AML: data from real life and clinical trials
          • Current approach to FLT3 mutated AML
          • Updates in treatment for high-risk AML
        • Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies
          • Triplet Combinations of Novel Therapies
          • Targeted Therapies and Novel Therapies
      • Lymphoma
        • Mantle Cell, Follicular, and Other B-Cell Lymphomas
          • Targeted Therapy in Low Grade Lymphoma
          • Evolution of Immunotherapeutic Regimens in B-cell Lymphomas
          • Front-line Induction Therapy and Novel Agents After Relapse
          • Advances in Treatment Approaches
        • Hodgkin Lymphomas and T/NK cell Lymphomas
          • T/NK Cell Lymphoma Frontline Clinical Trials
          • Hodgkin Lymphoma Clinical Trials
          • T/NK Cell Lymphoma Relapsed Therapy
          • Hodgkin Lymphoma Clinical Outcomes Data
        • Aggressive Lymphomas Prospective Therapeutic Trials
          • Challenging Populations
          • Novel Agents and Combinations
        • Aggressive Lymphomas: Clinical and Epidemiological
          • Population data for Aggressive NHL Management
          • Clinical Management of Aggressive B cell NHL
          • Real World evidence for CAR-T Management I
          • Real World evidence for CAR-T Management II
      • CML
        • Mechanisms of resistance and expanded therapies
        • Progress with response prediction and TKI discontinuation
      • Myeloprolifertive Syndromes
        • Non-JAK inhibitor Therapies for Myelofibrosis Clinically Relevant Abstract
        • Risk Stratification and Prognostication Clinically Relevant Abstract
        • Transplantation, COVID-19 and Biology Insights Clinically Relevant Abstract
        • Novel Therapies for MPNs and JAK inhibitors for Myelofibrosis
      • MDS
        • Low Risk Myelodysplastic Syndrome Prognosis and Treatment
        • Treatment of High Risk Myelodysplastic Syndrome
        • Treatment of HIgh Risk and Relapsed/Refractory Myelodysplastic Syndrome
      • CLL
        • Combination Small Molecules
        • Clinical and Epidemiological I
        • Clinical and Epidemiological II
      • Multiple Myeloma
        • Multiple Myeloma and Plasma cell Dyscrasias: Clinical and Epidemiological
          • Monoclonal Gammopathies of Determined Significance: What We Have and What We Want
          • A Map for the Changing Landscape of Multiple Myeloma
          • Multiple Myeloma and Waldenstrom Macroglobulinemia: Exploring Biomarkers in the Era of Personalized Medicine
          • Reoptimizing Standards and Redefining Approaches
          • Challenges in Multiple Myeloma Therapy: Adopting New Approaches for Relapse and Monitor
        • Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials
          • Phase 2 and 3 Trials in Myeloma
          • Novel Targets and Amyloid
          • Treatment of NDMM and amyloidosis patients
          • Immune Therapy for Multiple Myeloma
      • Cellular Therapies
        • Cellular Therapies for Lymphomas
        • Cellular Therapies-Immune Interactions, Lineage Switching and CNS targets
        • Cellular Therapies for ALL
        • Cellular Therapies for Myeloma
        • Allogeneic CARs and CARs for T Cell Lymphomas
        • Cellular Therapies for Low and High Grade Lymphomas
        • Expanding Targets and Cellular Sources for Immunotherapies
    • 2021 SAN ANTONIO BREAST CANCER SYMPOSIUM
      • Interviews
        • Ingo Bauerfeind, Landshut
        • Nina Ditsch, Augsburg
        • Nadia Harbeck, München
        • Nadia Harbeck, München
        • Christian Jackisch, Offenbach
        • Wolfgang Janni, Ulm
        • Hans-Christian Kolberg, Bottrop
        • Thorsten Kühn, Esslingen
        • Michael Lux, Paderborn
        • Volkmar Müller, Hamburg
        • Volkmar Müller, Hamburg
        • Christoph Thomssen, Halle (Saale).
        • Michael Untch, Berlin-Buch
        • Michael Untch, Berlin-Buch
        • Mathias Warm, Köln-Holweide.
        • Achim Wöckel, Würzburg
        • Rachel Würstlein, München
      • General Session 1
      • General Session 2
      • General Session 3
      • General Session 4
    • 9. Interdisziplinäres Prostatakarzinom-Symposium
    • Swiss Oncology & Hematology Congress (SOHC)
    • Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie
      • Kongress-Pressekonferenz
      • Ausgewählte Abstracts
        • COVID-19 und Krebs
        • Hämatologie
          • Multiples Myelom I
          • Multiples Myelom III
          • Multiples Myelom IV
          • Akute myeloische Leukämie I
          • Akute myeloische Leukämie II
          • Akute myeloische Leukämie III
          • Indolente Lymphome/CLL/Hodgkin-Lymphome I
          • Indolente Lymphome/CLL/Hodgkin-Lymphome II
          • Chronische myeloische Leukämie
          • Aggressive Lymphome/Akute lymphatische Leukämie II
        • Onkologie
          • Lungenkarzinom (inkl. Pleura) I
          • Lungenkarzinom (inkl. Pleura) II
          • Lungenkarzinom (inkl. Pleura) III
          • Sarkome/Seltene Tumore
          • Nierenzellkarzinom
          • Prostata-/Urothel-/Keimzell-Tumoren
          • Hepatobiläres Karzinom/Pankreas-Karzinom
          • Gastrointestinale Tumoren
          • Mammakarzinom/ Gynäkologische Malignome (Ovar, Uterus)
    • ESMO Congress 2021
      • Interviews
        • Interviews - Brustkrebs
          • Renate Haidinger, Brustkrebs Deutschland e.V. im Interview mit Hans-Christian Kohlberg, Bottrop
          • Renate Haidinger, Brustkrebs Deutschland e.V. im Interview mit Wolfgang Janni, Ulm
          • Renate Haidinger, Brustkrebs Deutschland e.V. im Interview mit Volkmar Müller, Hamburg
          • Renate Haidinger, Brustkrebs Deutschland e.V. im Interview mit Christoph Thomssen, Halle-Saale
          • Renate Haidinger, Brustkrebs Deutschland e.V. im Interview mit Christoph Thomssen, Halle-Saale
          • Renate Haidinger, Brustkrebs Deutschland e.V. im Interview mit Michael Untch, Berlin-Buch
          • Renate Haidinger, Brustkrebs Deutschland e.V. im Interview mit Michael Untch, Berlin-Buch
      • Friday, September 17
        • Proferred Paper Sessions
          • Genitourinary tumours, non-prostate 1
          • Non-metastatic NSCLC and other thoracic malignancies
          • Gynaecological cancers
          • Investigational immunotherapy
          • Breast cancer, early stage
          • Developmental therapeutics
        • Mini oral sessions 
          • Gastrointestinal tumours, non-colorectal
          • Investigational immunotherapy
          • Head and neck cancer, excl. thyroid
          • Supportive and palliative care
          • Sarcoma
          • Translational research
      • Saturday, September 18
        • Presidential symposium 1
        • Proffered Paper sessions
          • NSCLC, metastatic 1
          • Gastrointestinal tumours, colorectal
          • Genitourinary tumours, prostate
          • Melanoma and other skin tumours
          • Basic science
        • Mini oral sessions
          • Breast cancer, metastatic
          • Genitourinary tumours, non-prostate
          • Non-metastatic NSCLC and other thoracic malignancies
          • Gastrointestinal tumours, colorectal
          • Public policy
      • Sunday, September 19
        • Presidential symposium 2
        • Proffered Paper sessions
          • Breast cancer, metastatic
          • Genitourinary tumours, non-prostate 2
          • CNS tumours
          • Gastrointestinal tumours, non-colorectal
          • Translational research
        • Mini oral sessions
          • NSCLC, metastatic
          • Genitourinary tumours, prostate
          • Haematological malignancies
          • Basic science
          • Gynaecological cancers
      • Monday, September 20
        • Presidential symposium 3
        • Proffered Paper sessions
          • Head and neck cancer, excl. thyroid
          • Gastrointestinal tumours, colorectal 2
          • Haematological malignancies
          • NSCLC, metastatic 2
          • Public policy
        • Mini oral sessions
          • Breast cancer, early stage
          • Melanoma and other skin tumours
          • Developmental therapeutics
          • CNS tumours
          • NETs and endocrine tumours
      • Tuesday, September 21
        • Proffered Paper sessions
          • Sarcoma
          • NETs and endocrine tumours
          • Supportive and palliative care
          • SARS-CoV-2 and cancer
        • Mini oral session
    • 18th International Myeloma Workshop
      • Thursday, September 9
        • Oral Abstract Sessions
        • Oral Abstract Sessions
      • Friday, September 10
        • Oral Abstract Sessions
        • Oral Abstract Sessions
      • Saturday, September 11
        • Oral Abstract Sessions
    • Innovative Software-Lösung entlastet die Ärzteschaft in der Onkologie
    • ESMO World Congress on Gastrointestinal Cancer 2021
      • Session I:
      • Session II:
      • Session IV:
      • Session V:
      • Session VI:
      • Session VII:
      • Session VIII:
      • Session IX:
      • Session X:
    • International Conference on Malignant Lymphoma (ICML)
      • PLENARY SESSION
      • SESSION 1:
      • SESSION 2:
      • SESSION 3:
      • SESSION 4:
      • SESSION 5
      • SESSION 6:
      • SESSION 7:
      • SESSION 8:
      • SESSION 9:
      • SESSION 10:
      • SESSION 11:
      • SESSION 12:
      • SESSION 13:
    • EHA2021 Virtual Congress
      • Presidential Symposium
      • Late-Breaking Oral Session
      • Acute leukemia
        • ALL - CAR-T: Alternative targets and age groups
        • ALL - Novel subgroups and agents
        • Developments in AML therapy
      • Chronic myeloid malignancies
        • Response, resistance and treatment-free remission in CML
        • Population based studies in myeloid disorders
        • Novel targets in MDS
        • New pathways and molecular mechanisms in MPN
        • Novel therapies and targets in MPN
      • Chronic lymphoid malignancies
        • Clinical trials with targeted therapies in CLL
        • New treatment strategies for newly diagnosed multiple myeloma
        • New diagnostic and therapeutic approaches in multiple myeloma and AL amyloidosis
        • T cell re-directing therapies in relapsed/refractory multiple myeloma
      • Lymphoma
        • Hodgkin lymphoma - Clinical
        • Indolent & mantle cell lymphoma - Clinical
        • Aggressive lymphoma - CAR-T & transplant
        • Aggressive lymphoma - Combination therapies
      • Immunology
        • Cellular immunotherapy and gene therapy - Clinical
        • Fungal, bacterial and viral infections in hematology
      • Red & white cell disorders
        • New directions in aplastic anemia and PNH
        • Stem cell transplantation - GvHD
        • Stem cell transplantation - Clinical
        • Changing the scene on sickle cell disease
        • Changing the scene on thalassemias
    • 2021 ASCO Annual Meeting
      • Plenary Session (LBA's) & Presscast Presentations
      • Breast Cancer
        • Interviews
          • Früher Brustkrebs neoadjuvant: Talazoparib bei triple-negativer BRCA 1/2 Keimbahnmutation
          • #ASCO21: WSG-ADAPT HR+/HER2- Ergebnisse in der Hochrisikogruppe
          • #ASCO21: Neoadjuvante De-Eskalation in WSG-ADAPT HR-/HER2+
          • #ASCO21: Olaparib nach (neo)adjuvanter Chemotherapie bei Keimbahnmutation BRCA 1/2
          • #ASCO21: Bedeutung der CSF ctDNA beim triple-negativen Brustkrebs (neoadjuvant)
          • #ASCO21: GeparNUEVO - neoadjuvant Durvalumab beim triple-negativen Brustkrebs
          • #ASCO21: Highlights zum metastasierten Brustkrebs
          • #ASCO21: Patientenumfrage zur Dosisanpassung beim metastasierten Brustkrebs
          • #ASCO21: Brustkrebs Highlights local/regional/adjuvant
          • #ASCO21: Metastasierter hormonpositiver Brustkrebs - Update zu den CDK4/6 Inhibitoren
        • Breast Cancer—Local/Regional/Adjuvant
        • Breast Cancer—Local/Regional/Adjuvant
        • Breast Cancer—Metastatic
        • Breast Cancer—Metastatic
      • Gastrointestinal Cancer
        • Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
        • Gastrointestinal Cancer—Colorectal and Anal
        • Gastrointestinal Cancer—Colorectal and Anal
        • Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
      • Gynaecological Cancer
        • Gynecologic Cancer
        • Gynecologic Cancer
      • Haematological Malignancies
        • Hematologic Malignancies—Plasma Cell Dyscrasia
        • Hematologic Malignancies—Plasma Cell Dyscrasia
        • Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
        • Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
        • Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
        • Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
      • Head & Neck Cancer
        • Head and Neck Cancer
        • Head and Neck Cancer
      • Lung Cancer
        • Lung Cancer—Non-Small Cell Metastatic
        • Lung Cancer—Non-Small Cell Metastatic
        • Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
        • Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
      • Melanoma/Merkel cell carcinoma
      • Urogenital Cancer
        • Genitourinary Cancer—Kidney and Bladder
        • Genitourinary Cancer—Kidney and Bladder
        • Genitourinary Cancer—Prostate, Testicular, and Penile
        • Genitourinary Cancer—Prostate, Testicular, and Penile
    • American Association for Cancer Research (AACR) Annual Meeting 2021
      • Important Papers presented at the Press Conference
      • Important Papers presented in Press Releases
    • ELCC 2021
    • 47th Annual Meeting of the European Society for Blood and Marrow Transplantation
      • Choice of oral Sessions
        • CART-T Cells 1
        • CART-T Cells 2
        • Multiple Myeloma
      • Choice Educational Sessions
        • CAR-T Toxicity and Management
        • CARs in Childhood Malignancy
        • New developments in the field of CAR cell therapy
      • Satellite Symposia
        • Present and future approaches with CAR T cell therapy in B-cell malignancies
        • Targeting the immune system in multiple myeloma: CAR T cell therapy and beyond
    • Brustkrebsinfotag 2021
    • News der Leitlinienkommission der AGO Mamma 2021
    • 2nd Zurich Brain Metastasis Symposium
      • Experimental Studies
      • Keynote Lectures
      • Updates on Therapeutic Approaches
      • Brain Metastasis: Disease Updates
      • Controversies & Hot Topics in the Diagnosis and Management of CNS Metastasis
    • Second Zurich Lung Cancer Symposium
      • Lung Cancer Screening and Approach to Small Lesions
      • Molecular Pathology of Lung Cancer
      • Development in Stage III NSCLC Disease
      • The Improvement of Survival in Metastatic NSCLC
      • The Importance of Clinical Trials
      • Approach to Oligometastatic Disease
    • 4th Zurich Immuno-Oncology Symposium
      • Keynote Address
      • Therapeutic Developments I
      • Therapeutic Developments II
      • Challenges in Patient Management
      • Challenges in Optimizing Treatment
      • Cell-based Therapies
    • Cancer Academy – Immuntherapie
    • First Zürich Precision Oncology Symposium
      • Speakers
      • Molecular Testing and Molecular Tumor Board
      • Keynote address
      • Precision Oncology for Solid Tumors 1/Ongoing Research Activities 1
      • Precision Oncology for Solid Tumors 2
      • Precision Oncology for Hematologic Malignancies
      • Precision Oncology for Solid Tumors 2/Ongoing Research Activities 2
  • Kongressberichte 2020
    • 2020 San Antonio Breast Cancer Virtual Symposium
      • Press Briefing
      • Interviews geführt von Renate Haidinger, Brustkrebs Deutschland e.V.
        • Interview mit Ingo Bauerfeind, Landshut
        • Interview mit Nadia Harbeck, München
        • Interview mit Christian Jackisch, Offenburg
        • Interview mit Wolfgang Janni, Ulm
        • Interview mit Wolfgang Janni, Ulm
        • Interview mit Michael Patrick Lux, Würzburg
        • Interview mit Volkmar Müller, Hamburg
        • Interview mit Volkmar Müller, Hamburg
        • Interview mit Christoph Thomssen, Halle (Saale)
        • Interview mit Michael Untch, Berlin-Buch
        • Interview mit Michael Untch, Berlin-Buch
        • Interview mit Achim Wöckel, Würzburg
        • Interview mit Achim Wöckel, Würzburg
      • General Sessions
        • GENERAL SESSION 1:
        • GENERAL SESSION 2:
        • GENERAL SESSION 3:
        • GENERAL SESSION 4:
    • All-Virtual 62nd ASH Annual Meeting and Exposition
      • Press Briefings
        • Press Briefing on Disparities in Health Care: Diversity, Equity, and Inclusion (DEI)
        • Press Briefing on What’s on the Horizon: Practice-Changing Clinical Trials
        • Press Briefing on Hematologic Aspects of the Pandemic: Advancing the Study of COVID-19
        • Press Briefing on Advancing New Frontiers: Genome Editing & Cellular Therapy
        • Press Briefing on Selected Late-Breaking Abstracts
      • Plenary Scientific Session
      • Late-Breaking Abstracts Session
      • Choice of two Scientific Workshops on Lymphoid Malignancies
        • Scientific Workshop on Tumor Immune Interactions
        • Scientific Workshop on Tumor Immune Interactions
      • Satellite Symposia
        • Exploring Antibody Therapy in ALL: How and Why to Integrate Antibody-Based Treatment Into Patient Management
        • Medical Crossfire®:Exploring the Modern Management of Acute Lymphoblastic Leukemia from AYA to Adult
        • A Fresh Look at CAR T-Cell Therapy: Recent Advances, New Evidence, and Evolving Paradigms to Improve Patient Care
      • Oral Sessions
        • Hemoglobinopathies
          • Hydroxyurea for Sickle Cell Disease
          • Sickle Cell Disease
          • Sickle Cell Disease
        • Coagulation & Platelet Disorders
          • Disorders of Platelet Number or Function
          • Disorders of Platelet Number or Function
        • Acute Lymphoblastic Leukemia
          • ALL - Clinical Studies
          • ALL - Clinical Studies
          • ALL - Therapy, excluding Transplantation
          • ALL - Therapy, excluding Transplantation
          • Choice of Posterpresentations with Pegaspargase
        • Acute Myeloid Leukemia
          • AML
          • AML
          • AML
          • AML
          • AML
          • AML - Novel Therapy, excluding Transplantation I
          • AML - Novel Therapy, excluding Transplantation II
          • AML - Novel Therapy, excluding Transplantation III
          • AML - Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis I
          • AML - Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis II
          • AML - Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis III
        • Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma
          • Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma
          • Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma
          • Mantle Cell and Indolent B-Cell Lymphoma
        • Hodgkin Lymphoma and T/NK Cell Lymphoma
          • Hodgkin Lymphoma and T/NK Cell Lymphoma
          • Hodgkin Lymphoma and T/NK Cell Lymphoma
          • Hodgkin Lymphoma and T/NK Cell Lymphoma
        • Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)
          • Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)
          • Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)
          • Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)
          • Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)
          • Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)
        • Chronic Myeloid Leukemia
          • Chronic Myeloid Leukemia
          • Chronic Myeloid Leukemia
        • Myeloproliferative Syndromes
          • Myeloproliferative Syndromes
          • Myeloproliferative Syndromes
          • Myeloproliferative Syndromes
        • Myelodysplastic Syndromes
          • Myelodysplastic Syndromes
          • Myelodysplastic Syndromes
        • CLL
          • CLL
          • CLL
        • Myeloma/Amyloidosis: Therapy excluding Transplantation:
          • Myeloma/Amyloidosis: Therapy excluding Transplantation
          • Myeloma/Amyloidosis: Therapy excluding Transplantation
          • Myeloma/Amyloidosis: Therapy excluding Transplantation
          • Myeloma/Amyloidosis: Therapy excluding Transplantation
          • Myeloma/Amyloidosis: Therapy excluding Transplantation
          • Myeloma/Amyloidosis: Therapy excluding Transplantation
    • 52th Congress of the International Society of Paediatric Oncology (SIOP)
      • Sessions Highlights
        • Wednesday
        • Thursday
        • Friday
        • Saturday
      • Building Bridges to ensure best possible outcomes for children and adults with ALL
    • DGHO, OeGHO, SGMO und SGH+SSH Jahrestagung 2020 VIRTUAL
      • Best Abstracts
      • Innovative Hämatologie
    • EBCC-12 European Breast Cancer Conference
    • ESMO VIRTUAL 2020
      • Presidential Symposia
        • Presidential Symposium I
        • Presidential Symposium II
        • Presidential Symposium III
      • Breast cancer
        • Interviews
        • Proffered Paper - Breast cancer, early stage
        • Proffered Paper - Breast cancer, metastatic 1
        • Proffered Paper - Breast cancer, metastatic 2
      • Thoracic Cancer
        • Proffered Paper - Non-metastatic NSCLC and other thoracic malignancies
        • Proffered Paper - NSCLC metastatic 1
        • Proffered Paper - NSCLC metastatic 2
      • CNS- & Skin Tumours, NETs & Sarcoma
        • Proffered Paper - NETs
        • Proffered Paper - Sarcoma
        • Proffered Paper - CNS tumours
        • Proffered Paper - Melanoma and other skin tumours
      • GU Tumours
        • Proffered Paper - GU, non prostate 1
        • Proffered Paper - GU, non prostate 2
        • Proffered Paper - GU, prostate
      • Gynaecological Cancers
        • Proffered Paper 1 - Gynaecological cancers
        • Proffered Paper 2 - Gynaecological cancers
      • Head & Neck & GI Cancers
        • Proffered Paper - Head & Neck cancer
        • Proffered Paper - GI, colorectal
        • Proffered Paper - GI, non colorectal
      • Immunotherapy, Translational Research & Basic Science
        • Proffered Papers - Investigational immunotherapy
        • Proffered Papers - Developmental therapeutics
        • Proffered Papers - Basic Science
        • Proffered Papers - Translational research
      • SARS-CoV-2 & Cancer
        • Proffered Paper - SARS-CoV-2 and cancer 1
        • Proffered Paper - SARS-CoV-2 and cancer 2
      • Supportive & Palliative Therapy, Public Policy
        • Proffered Paper - Supportive and palliative care
        • Proffered Paper - Public Policy
      • ESMO VIRTUAL CONGRESS 2020
    • VIRTUAL EBMT 46th Annual Meeting 2020
      • CAR-based Cellular Therapy
        • ACUTE LYMPHOBLASTIC LEUKEMIA
        • LARGE B-CELL LYMPHOMA
        • NON-HODGKIN LYMPHOMA
        • MULTIPLE MYELOMA
        • SIDE EFFECTS
        • MISCELLANEOUS
    • IASLC 21st World Conference on Lung Cancer
    • The 22nd ESMO World Congress on Gastrointestinal Cancer - Virtual Congress
      • Session I: Cancer of the Pancreas and Biliary Tract
      • Session II: Hepatocellular Cancer
      • Session III: Esophageal and Gastric Cancer
      • Session IV: Gastrointestinal Stromal Tumors (GIST); Neuroendocrine Tumors (NET)
      • Session V: Molecular Screening; Imaging; Artificial Intelligence
      • Session VI: Colorectal Cancer I
      • Session VII: Colorectal Cancer II
      • Session IX: Rectal Cancer
    • Virtual Edition of the 25th Annual Congress of the European Hematology Association
      • Presidential Symposium
      • Plenary Session I
      • Plenary Session II
      • Late-Breaking Oral Session - available fromSaturday June 13 8.30 AM
      • Oral Sessions
        • Acute Leukemia
          • ALL:
          • AML:
        • Lymphoma
          • Aggressive Lymphomas
          • Hodgkin lymphoma - Clinical
          • Indolent and mantle-cell non-Hodgkin lymphoma:
        • Chronic Myeloid Neoplasms
          • CML clinical
          • MDS:
          • MPN (Myelofibrosis & Hypereosinophilic Syndrome)
        • Chronic Lymphoid Neoplasms
          • CLL:
          • Multiple Myeloma
        • Immunology
          • CART cells
          • Immunotherapy:
          • Stem cell transplantation:
        • Red & White Cell Disorders
          • Iron in focus
          • Sickle cell disease:
          • Thalassemia:
        • ITP:
      • Link to Satellite Session - Live Fri 12 Jun 17:30-18:30
      • e-Poster Presentations
    • ASCO20 Virtual Scientific Meeting
      • Studies presented at press briefings
        • Pre-Meeting Presentation
        • Press Briefing May 28
      • Plenary Session Abstracts
      • Oral Sessions
        • Breast Cancer I
        • Breast Cancer II
        • Brustkrebs Interviews
        • Gynecologic Cancer
        • Gynäkologische Karzinomata - Interviews
    • SAMO Virtual Workshop on COVID19:
    • Coronavirus/Brustkrebs
    • AGO MAMMAKARZINOM - State of the Art Meeting 2020
      • Keynote-Lecture: Fatima Cardoso
      • Vormittag 1
      • Vormittag 2
      • Nachmittag 1
      • Nachmittag 2
      • Interviews im Rahmen einer Kooperation von Oncoletter mit Brustkrebs Deutschland e.v.
        • Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Andreas Schneeweiss, Heidelberg, zum Thema:
        • Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Volkmar Müller, Hamburg und Wolfgang Janni, Ulm, zum Thema:
        • Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Diana Lüftner Berlin, zum Thema:
        • Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Christian Jackisch, Offenbach & Andreas Schneeweiss, Heidelberg, zum Thema:
        • Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Bernd Gerber, Rostock zum Thema:
        • Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Volkmar Müller und Ute-Susann Albert, Frankfurt, zum Thema:
        • Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Achim Rody, Lübeck, zum Thema:
        • Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Achim Wöckel, Würzburg und Christoph Thomssen, Halle zum Thema:
        • Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Michael Lux, Erlangen, zum Thema:
        • Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit David Krug, Kiel, zum Thema:
        • Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Christoph Thomssen, Halle, zum Thema:
        • Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Nina Ditsch, München, zum Thema:
        • Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Marc Thill, Frankfurt und Michael Untch, Berlin, zum Thema:
        • Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Tanja Fehm, Düsseldorf und Elmar Stickeler, Aachen, zum Thema:
        • Gespräch mit Kerstin Rhiem, Köln, zum Thema:
        • Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Jens Huober, Ulm, zum Thema:
        • Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Thorsten Kühn, Esslingen und Jens Uwe Blohmer, Berlin, zum Thema:
        • Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Hans H. Kreipe, Hannover, zum Thema:
        • Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Ingo Bauerfeind, Landshut und Nina Ditsch, München, zum Thema:
    • Ten Years of ETOP
    • SABCS - 42nd Annual San Antonio Breast Cancer Symposium
      • Press Conferences
        • Wednesday, Dec. 11
        • Thursday, Dec. 12
        • Friday, Dec. 13
      • General Sessions 1-6
        • GENERAL SESSION 1:
        • GENERAL SESSION 2:
        • GENERAL SESSION 3:
        • GENERAL SESSION 4:
        • GENERAL SESSION 5:
        • GENERAL SESSION 6:
      • Interviews - Breast Cancer
        • HER 2-positiver, metastasierter Brustkrebs: HER2CLIMB Studie mit Tucatinib
        • HER 2-positiver, metastasierter Brustkrebs: DESTINY-Breast01 Studie mit Trastuzumab Deruxtecan
        • HER 2-positiver Brustkrebs adjuvant: APHINITY Studie, 2. Zwischenanalyse
        • HER 2-positiver Brustkrebs adjuvant: ATEMPT Studie T-DM1 gegen Paclitaxel plus Trastuzumab
        • Einsatz von Capecitabine Neo/Adjuvant
        • GEPARX Studie: Denosumab im Vergleich zu zwei Nab-Paclitaxel Schemata - neoadjuvant
        • Immuncheckpoint-Inhibitoren: Durvalumab beim metastasierten BC und Pembrolizumab neoadjuvant und adjuvant bei TNBC
        • pCR bei neoadjuvanter Therapie mit Atezolizumab beim TNBC?
        • Neues zu CDK4/6 Inhibitoren (HR+ & HER2-)
        • Wenn der Brust-Tumor weg ist nach neoadjuvanter Therapie: Muss noch operiert werden?
        • Teil- oder Ganzbrustbestrahlung nach Brust erhaltender Therapie. Was für wen?
      • Schweizer Expertenrunde mit einigen Highlights vom SABCS:
      • Round Table mit Brustkrebs Deutschland e.V.
    • 61st ASH Annual Meeting and Exposition
      • Highlights of the Conference: Statements & Opinions
        • ALL
        • Multiples Myelom
        • Multiples Myelom
        • Lymphome
      • Press Briefings
        • Saturday, December 7:
        • Saturday, December 7:
        • Saturday, December 7:
        • Sunday, December 8:
        • Monday, December 9 (embargoed until Tuesday 7:30 AM EST):
      • Late Breaking Abstract Session
      • Acute Lymphoblastic Leukemia (excluding Transplantation)
        • Therapeutic Strategies
        • Novel Therapies
        • Clinical Studies - Choice of Poster-Abstracts with Asparaginase
        • CAR T Cells--Refining the Approach
        • Chemo Immuno and Targets--Improving Combinations in ALL
      • Acute Myeloid Leukemia (excluding Transplantation)
        • Clinical Studies: Non-Intensive Therapy
        • Intensive Upfront Chemotherapy
        • Treatment of Relapsed/Refractory Disease
        • Induction and Post-Remission Therapy
        • New Treatment Strategies
        • Novel Immunotherapeutics, Checkpoint Inhibitors, and BiTEs
        • Novel Targets and Combinations
      • Chronic Myeloid Leukemia: Therapy
        • Predictors of TKI Discontinuation and TFR Outcomes
        • Clinical Trials and Outcomes
        • Response Monitoring and Prognosis
      • Myeloproliferative Syndromes
        • Emerging and Novel Targeted Therapies
        • JAK Inhibitors and Combination Therapies
      • Myelodysplastic Syndromes
        • Combination Therapies
        • Targeting Gene Mutations in MDS
        • Lower-Risk MDS and CMML
        • SAKK POSTER
      • Myeloma: Therapy, excluding Transplantation
        • New Approaches in the Treatment of Relapsed/Refractory Plasma Cell Discrasias
        • Novelty in CAR T in Relapsed/Refractory Multiple Myeloma
        • Therapeutics Questions in Newly Diagnosed Myeloma
        • Improving the Outcomes of Newly Diagnosed Multiple Myeloma
        • Novel Therapy for Relapsed Myeloma
      • CLL (excluding Transplantation)
        • First Line Treatment
        • Combination and Novel Treatment
        • BTK Inhibitors and CAR T Cells in CLL
      • Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies
        • Follicular Lymphoma: Biomarkers and Clinical Trials
        • Clinical Trials in Waldestrom's Macroglobulinemia and Other Indolent B-cell Non-Hodgkin Lymphomas
        • Mantle Cell Lymphoma: Frontline and Relapsed Therapies
      • Hodgkin Lymphoma and T/NK Cell Lymphoma
        • Combination Chemotherapy and Biomarkers of Response in Hodgkin Lymphoma
        • Immunotherapy Approaches in Hodgkin Lymphoma
        • Novel Therapies in Peripheral T-cell Lymphomas
      • Aggressive Lymphoma (DLBC and Other Aggressive B-Cell Non-Hodgkin Lymphomas
        • Results from Prospective Clinical Trials: Optimizing Frontline Chemotherapy
        • Results from Prospective Clinical Trials: Results from CAR T-Cell Trials  
        • Novel Therapies in Relapsed/Refractory Disease
        • Results from Retrospective/Observational Studies: Population-Based Outcomes
        • Results from Retrospective/Observational Studies: Prognostic Markers
        • Results from Retrospective/Observational Studies: Cellular Therapies
      • Immunotherapies
        • Immunotherapies I
        • Immunotherapies II
    • Gene Therapy and Transfer
      • Advancing CAR T Cells: New Biology and Therapeutic Applications
      • Gene Therapies for Non-Malignant Disorders
    • CAR-T-Zell Therapie in der Schweiz
  • Kongressberichte 2019
    • 6th ICIS Expert Meeting on “Critical questions in immune thrombocytopenia in children and adults”
      • Welcome
      • Session 1
      • Session 2
      • Session 3
      • Session 4
    • 8. Interdisziplinäres Prostatakarzinom-Symposium 2019
      • I Grundlagen und Früherkennung
      • II Lokoregionäre Therapie des Prostatakarzinoms
      • III Aspekte der Systemtherapie des Prostatakarzinoms
    • Jahrestagung 2019 von DGHO, OeGHO, SGMO und SGH+SSH
      • Pressekonferenz
    • OnkoZentrum Zürich - Patientenforum 2019
    • ESMO 2019
      • Press Briefings
        • Opening Press Conference
        • Lung and gynaecological cancers
        • Breast cancer
        • Gastrointestinal and genitourinary cancers
      • SAKK Studien am ESMO 2019
      • Brustkrebs
      • Gastrointestinal Cancers
        • Metastatic Colorectal Cancer (mCRC)
        • More from BEACON CRC & TAILOR
        • Metastatic Gastric, Pancreatic & Biliary Cancer
      • Lung Cancer, Mesothelioma & Head and Neck Cancer
      • Melanoma
      • Ovarialkarzinom
    • Cancer Academy - Kopf-Hals-Tumore
    • IASLC 2019 World Conference on Lung Cancer (#WCLC19)
      • Interviews
      • Press Briefings
        • Saturday, September 7th Press Briefing
        • Sunday, Sept. 8th Press Briefing
        • Monday, Sept 9th (Presidential Symposium Press Briefing)
        • Tuesday, Sept 10th Press Briefing
    • ESMO World Congress on Gastrointestinal Cancer
      • Press Conferences (News being made available according embargo rules)
        • Wednesday, 3 July - Opening Press Conference
        • Thursday, 4 July - Key studies of the day
        • Friday, 5 July - Key studies of the day
      • Session II: Cancer of the Pancreas and Biliary Tract
      • Presentation of Selected GI Cancer Abstracts
      • Presentation of Selected Rectal Cancer Abstracts
      • Session VII: Gastric Cancer - Presentation of Selected Abstracts
      • Session XII: Presentation of Selected Abstracts: Emerging New or Combination Drugs in GI Cancer Part 1
      • Session XII: Presentation of Selected Abstracts: Emerging New or Combination Drugs in GI Cancer Part 2
      • Session XI: Presentation of Selected Abstracts: Colorectal Cancer - Part 1
      • Session XI: Presentation of Selected Abstracts: Colorectal Cancer - Part 2
      • Session XVI: Hepatocellular Cancer - Presentation of Selected Abstracts
      • Session XX: Colorectal Cancer (Part I) - Presentation of Selected Abstracts & Comments Roger von Moos and Thomas Winder
    • 15th International Conference on Malignant Lymphoma (ICML)
      • Introductory Press Conference
      • PLENARY SESSION
      • MULTIPLE MYELOMA: EVERY YEAR A NEW STANDARD?
      • HOW TO APPROACH CLL IN CLINICAL PRACTICE
      • THE MODERN APPROACH TO MANTLE CELL LYMPHOMA
      • MANTLE CELL LYMPHOMA
      • PET IMAGING
      • PEDIATRIC LYMPHOMA
      • RESULTS FROM SINGLE AGENT TRIALS
      • ONGOING TRIALS
      • DLBCL: CLINICAL DATA
      • CLL
      • TREATMENT WITH NOVEL ANTIBODIES
      • T-CELL LYMPHOMAS
      • CLL AND MORE
      • CHEMOTHERAPY-FREE STRATEGIES
      • NON-CLINICAL AND EARLY CLINICAL DATA WITH NEW COMBINATIONS
      • HIGH RISK LARGE B-CELL LYMPHOMAS
      • LYMPHOMA PATHOLOGY
      • HODGKIN LYMPHOMA
      • FOLLICULAR LYMPHOMA
      • EXTRANODAL LYMPHOMAS
      • NEW DATA ON T-CELL AND OTHER LYMPHOMAS
      • ADVANCES IN CAR T-CELL TREATMENT
      • NEW DRUG COMBINATIONS
      • INDOLENT NON-FOLLICULAR LYMPHOMA
    • 24th Congress of EHA
      • Presidential Symposium
      • Late-breaking oral presentations (6 best abstracts)
      • Important presentations at Press Briefings
        • Friday, June 14, 2019
        • Saturday, June 15, 2019
      • Indolent and mantle-cell non-Hodgkin Lymphoma - clinical
      • Aggressive lymphomas - New agents
      • Aggressive lymphomas - First line, combination therapy and real-life data - Aggressive non-Hodgkin lymphoma
      • Hodgkin lymphoma - clinical
      • Novel agents and therapies for CLL
      • New stratification and treatment approaches in ALL - including CAR T Cell therapy
      • Advances in the management of thalassemia
      • Immunotherapy in relapsed/refractory multiple myeloma
      • Novel strategies in multiple myeloma
      • Novel agents for newly diagnosed plasma cell dyscrasias
      • Myeloma and other monoclonal gammopathies - Clinical
      • New therapies in AML
      • Gene therapy, cellular immunotherapy and vaccination - Biology & translational research
      • Gene therapy, cellular immunotherapy and vaccination - Clinical
      • Update on clinical trials in MPN
      • New agents in MPN
    • Annual Meeting of the American Society of Clinical Oncology 2019
      • Press Briefings
        • May 15 Presscast
        • Press Briefing Saturday June 1:
        • Press Briefing Sunday June 2:
        • Press Briefing Monday June 3:
      • Breast Cancer
        • Breast Cancer News Interviews
          • Sind biosimilare Antikörper beim Brustkrebs genauso wirksam wie das Original?
          • Metastasierter HER2-positiver Brustkrebs
          • Immuntherapie bei Brustkrebs
          • MONALEESA 7: Überlebensvorteil für prämenopausale Frauen mit Ribociclib
          • Seltene Brustkrebsarten
          • Brustkrebs beim Mann
          • Lymphknotenbefall vor und nach neoadjuvanter Chemotherapie (transSENTINA 5)
          • T-DM1 neoadjuvant bei HER2-positivem Mammakarzinom (KRISTINE)
        • Breast Cancer News Aufzeichnung Live-Stream
        • Oral & Poster Presentations
      • Colon Cancer
        • Oral Presentations
        • Poster Presentations
      • Other gastrointestinal Cancer
        • Oral Presentations
        • Poster Presentations
      • Other Gynaecologic Cancers
      • Head & Neck Cancers
        • Oral Presentations
        • Poster Presentations
      • Lung Cancer
      • Hauttumore
      • Urogenital Cancers
        • Oral Presentations
        • Poster Presentations
      • Hematology
        • Multiple Myeloma & Myelofibrosis
        • Lymphoma & CLL
        • ALL
    • Senologie Update 2019
      • Teil 1:
      • Teil 2:
      • Teil 3:
      • Teil 4:
    • ELCC 2019 - European Lung Cancer Congress | ESMO 10-13 April 2019 Geneva, Switzerland
    • BCC2019
      • Opening and Award Ceremony:
      • Session 1: News since St.Gallen 2017
      • Session 2: Biology of Breast Cancer I: Risk stratification
      • Session 3: Biology of breast cancer II: Prediction of response
      • Session 4: Risk stratification and prevention in ductal in situ carcinoma
      • Special lecture I and II
      • Session 5: New pathways with potential impact in the treatment of early breast cancer
      • Session 6: Treatment tailoring according to pathology and biology
      • Session 7: Surgery of early breast cancer
      • Session 8: Radiotherapy of early breast cancer
      • Special lecture III
      • Session 9: Primary and adjuvant systemic therapy of early breast cancer: Estimating the magnitude of clinical benefit I
      • Session 10: Primary and adjuvant systemic therapy of early breast cancer: Estimating the magnitude of clinical benefit II
      • GenomicHealth interactive satellite symposium in conjunction with the 16th St Gallen International Breast Cancer Conference
      • Nanostring Satellite Symposium: Recent Breakthroughs for HR+/HER2- Early Breast Cancer Patients:
      • Interviews (in German): Renate Haidinger, Brustkrebs Deutschland e.V. im Gespräch
      • Three SAKK Posters
    • 45th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)
      • Interviews
      • Presidential Symposium
        • GS2-2 - IMPROVED SURVIVAL OF AML- AND MDS-PATIENTS AFTER TREOSULFAN-BASED COMPARED TO REDUCED‑INTENSITY BUSULFAN-BASED CONDITIONING-REGIMEN FOR ALLOGENEIC HAEMATOPOIETIC CELL TRANSPLANTATION: FINAL RESULTS OF A PROSPECTIVE RANDOMISED PHASE-III-TRIAL
        • GS2-3 - GRAFT-VERSUS-LEUKEMIA EFFECT AFTER HAPLO-IDENTICAL STEM-CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE IN AML- NO ASSOCIATION WITH GRAFT-VERSUS-HOST-DISEASE: A STUDY OF THE ACUTE LEUKEMIA WORKING PARTY OF EBMT
        • GS2-4 - SEQUENTIAL CD19- AND CD22-CART CELL THERAPIES FOR RELAPSED B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: 10-MONTH MEDIAN FOLLOW-UP
        • GS2-5 - ALLOGENEIC STEM CELL TRANSPLANTATION FROM HAPLOIDENTICAL DONORS VERSUS MATCHED OR MISMATCHED 9/10 UNRELATED DONORS IN ACUTE LYMPHOBLASTIC LEUKEMIA IN FIRST COMPLETE REMISSION
        • GS2-6 - LOW-DOSE INFUSIONS OF CD45RA DEPLETED DONOR LYMPHOCYTES AFTER
 TCR ALPHA/BETA-DEPLETED TRANSPLANTATION IN PATIENTS WITH NON-MALIGNANT DISORDERS
        • GS2-7 - CELL-MEDIATED IMMUNOGENICITY OF THE ADJUVANTED RECOMBINANT ZOSTER VACCINE (RZV) IN ADULT AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS: A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED ZOE-HSCT CLINICAL TRIAL
      • Oral Session 9: Late-breaking abstracts
        • OS9-1 - COMPARABLE OUTCOME AFTER 10/10 AND 9/10 HLA-MATCHED UNRELATED DONOR STEM CELL TRANSPLANTATION (HSCT) USING POST-TRANSPLANT CYCLOPHOSPHAMIDE (PTCY) FOR GVHD PROPHYLAXIS, ON BEHALF OF THE ALWP-EBMT.
        • OS9-2 - MYELOABLATIVE CONDITIONING FOR FIRST ALLOGENEIC HSCT IN PEDIATRIC ALL: FTBI OR CHEMOTHERAPY? - AN UPDATE OF THE RETROSPECTIVE MULTICENTER EBMT-PDWP STUDY
        • OS9-3 - THE DETECTION OF THE SOLUBLE EBV ZEBRA PROTEIN AS A NEW PREDICTIVE BIOMARKER FOR PTLD
        • OS9-4 - EFFECTIVE CANCER IMMUNOTHERAPY WITH ERBB2-CAR-ENGINEERED CYTOKINE-INDUCED KILLER (CIK) CELLS IN HIGH-RISK SOFT TISSUE SARCOMAS
        • OS9-5 - GENESIS - A PHASE III RANDOMIZED DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, EVALUATING SAFETY AND EFFICACY OF BL-8040 AND G-CSF IN MOBILIZATION OF HCS´S FOR AUTOLOGOUS TRANSPLANTATION-MULTIPLE MYELOMA
        • OS9-6 - REAL LIFE EXPERIENCE IN THE TREATMENT OF PEDIATRIC, ADOLESCENT AND YOUNG ADULT ALL PATIENTS USING COMMERCIALLY AVAILABLE CAR-T-CELLS
      • How Do I... manufacture T cells for cellular therapies
        • HDI1-1 - Manufacturing of virus-specific T cells at an academic center
        • HDI1-2 - CAR T manufacturing in an academic setting
        • HDI1-3 - Low-dose memory T cell DLI for infection prophylaxis
      • How Do I... manage patients after CAR T-cell therapy.
        • HDI8-1 - Lymphoma, CLL and ALL
        • HDI8-2 - Myeloma patients
        • HDI8-3 - From a nurse's perspective
      • New developments in the field of CAR cell therapy
        • P2-1 - State of the art for ex-vivo manufactured autologous CAR T-cells
        • P2-2 - Simultaneous targeting of CD19 and CD22 with a bicistronic CAR - preliminary results of the AMELIA study
        • P2-3 - Off-the-shelf CAR NK cells for the treatment of hematologic malignancies
        • P2-4 - CAR T-cells against solid tumors: TRUCKs on the road
    • AGO MAMMAKARZINOM - State of the Art Meeting 2019
      • Vormittag 1
      • Vormittag 2
      • Nachmittag 1
      • Nachmittag 2
      • Interviews: Renate Haidinger, Brustkrebs Deutschland e.V. im Gespräch
  • Kongressberichte 2018
    • SABCS - 41st Annual San Antonio Breast Cancer Symposium
      • Press Conferences
        • Wednesday, Dec. 5, Press Conference 1
        • Wednesday, Dec. 5, Press Conference 2
        • Thursday, Dec. 6 Press Conference
        • Friday, Dec. 7 Press Conference
      • Schweizer Poster am SABCS
      • Interviews - Breast Cancer
        • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Christian Jackisch, Offenbach
        • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Michael Untch, Berlin-Buch
        • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Michael Patrick Lux, Erlangen
        • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Achim Rody, Lübeck
        • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Nadia Harbeck, München:
        • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Nadia Harbeck, München:
        • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Volkmar Müller, Hamburg
        • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Christoph Thomssen, Halle/Saale
        • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Cornelia Liedtke, Berlin
        • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Priv.-Doz. Dr. med. Hans-Christian Kolberg in Bottrop
        • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Thorsten Kühn, Esslingen
        • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Michael Wilhelm Braun, München
        • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Wolfgang Janni, Ulm
        • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Wolfgang Janni, Ulm
        • Dr. Petra Ortner, JOURNAL ONKOLOGIE im Gespräch mit Prof. Dr. med. Sibylle Loibl, Frankfurt
        • Dr. Petra Ortner, JOURNAL ONKOLOGIE im Gespräch mit Prof. Dr. med. Michael Untch, Berlin-Buch
        • Dr. Petra Ortner, JOURNAL ONKOLOGIE im Gespräch mit Dr. Rachel Würstlein, München
        • Dr. Petra Ortner, JOURNAL ONKOLOGIE im Gespräch mit Dr. med. Jörg Schilling, Berlin
        • Dr. Petra Ortner, JOURNAL ONKOLOGIE im Gespräch mit Priv.-Doz. Dr. med. Hans-Christian Kolberg, Bottrop
        • Dr. Petra Ortner, JOURNAL ONKOLOGIE im Gespräch mit Dr. med. Lothar Müller, Onkologie Unterems
      • Schweizer Expertenrunde mit einigen Highlights vom SABCS:
      • Round Table mit Brustkrebs Deutschland e.V.
      • General Sessions
        • GENERAL SESSION 1:
        • GENERAL SESSION 2:
        • GENERAL SESSION 3:
        • GENERAL SESSION 4:
        • GENERAL SESSION 5:
        • GENERAL SESSION 6:
    • American Society of Hematology (ASH) 60th Annual Meeting and Exposition
      • Statements & Opinions from some Highlights of the Conference
        • PD Dr. med. Nicolas Bonadies, Bern
        • Prof. Dr. med. Christoph Driessen, St. Gallen
        • Prof. Dr. med. Christoph Renner, Zürich
      • Press Briefings
        • Saturday December 1
          • Improving Sickle Cell Disease Outcomes in the U.S. and Africa
          • Major Trials Show Benefits of New Therapy Regimens for Cancer and Blood Disorders
          • CAR T-Cell Therapies: New Research and Updates from Pivotal Trials
        • Sunday December 2
        • Monday December 3
          • Late-Breaking Abstracts - Non-Malignant
          • Late-Breaking Abstracts - Malignant
      • Late-Breaking Abstracts Session
      • Myeloma: Therapy and upfront autologous Transplantation
        • Novel Antibody Combinations in Myeloma
        • Novel Targeted Combinations in Myeloma
        • Antibodies and Targeted Therapies
        • Novel Proteasome Inhibitors
        • Immunotherapies in Plasma Cell Disorders
        • Immunotherapy
        • Upfront Autologous Transplantation
        • Choice of Myeloma Posters
      • AML
        • Acute Myeloid Leukemia - Clinical Studies
          • Immunotherapy and New Agents
          • Minimal Residual Disease and Genetic Characterization
          • Maintenance after Allogeneic Stem Cell Transplant and Management of Refractory/Relapsed AML
        • Acute Myeloid Leukemia - Commercially Available Therapy, excluding Transplantation:
          • Optimal Induction and Re-Induction Regimens For Acute Myeloid Leukemia
          • Targeted Therapy For Adults Diagnosed With Acute Myeloid Leukemia
        • Acute Myeloid Leukemia - Novel Therapy, excluding Transplantation
          • Combination Therapy
          • Targeted Therapy
          • New Treatment Strategies
          • Immunotherapy
      • Lymphoma
        • Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies
          • Prognostic Markers and Therapies in Mantle Cell Lymphoma and Waldenstrom's Macroglobulinemia
          • Novel Therapies and Prognostic Assessment in Hairy Cell Leukemia and Indolent Non-Hodgkin Lymphoma
          • Antibodies, Immunomodulators, and BTK Inhibitors in Indolent NHL
        • Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies
          • Immunotherapy and Targeted Strategies
          • Hodgkin Lymphoma: Chemotherapy and Response Adapted Approaches
          • T Cell Lymphoma: Chemotherapy and Targeted Approaches
        • Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Prospective Clinical Trials
          • Immunotherapy
          • New Agents
          • Initial Treatment
        • Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Retrospective/Observational Studies
          • Outcomes With CD19 CAR T Therapy and Checkpoint Blockade in the Real World Setting
          • Prognostic Biomarkers and Molecular Signatures for Risk Stratification
          • Population Based Outcomes in Aggressive Lymphoma
          • Outcomes Of Lymphoma In The Elderly
      • Acute Lymphoblastic Leukemia: Clinical Studies & Therapy Excluding Transplantations
        • Improving Outcomes with Cellular Therapy
        • Improving Frontline Therapy in ALL
        • Chimeric Antigen Receptor T-cell therapy in ALL: What Is Next?
        • Targeted Therapy in ALL: Immunotherapy and Beyond
      • CLL: Therapy, excluding Transplantation:
        • Measurable Residual Disease in CLL: Moving Towards a Cure
        • Cellular Therapy and Immunomodulation in CLL
        • Advances in CLL Using Novel Combination Therapy
      • Chronic Myeloid Leukemia: Therapy
        • Epidemiology, Prognosis, and Real Life Care
        • First Line Trials and Prognostic Factors of Treatment-Free Remission
        • TFR Failure, Resistance, and New Drug Development
      • Myelodysplastic Syndromes—Clinical Studies: Novel Therapeutics, Prognosis and Prediction
        • Novel Therapeutics I
        • Novel Therapeutics II
        • Prognosis and Prediction
      • Scientific, medical, clinical, relevant “asparaginase” related Presentations
      • Health Services & Outcome Research—Malignant Diseases
      • Clinical Trials for Hemophilia and Using CAR T Cells
      • Thalassemia and Globin Gene Regulation
    • Cancer Academy: Sarkome, Früherkennung, Diagnose und Behandlung
    • ESMO 2018 Congress
      • Press Briefings
        • Breast Cancer
        • Ovarian Cancer
        • Prostate & Kidney Cancers
        • Head & Neck Cancer
        • All ESMO 2018 Press Releases
      • Interviews
        • Interviews - Breast Cancer
          • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Michael Untch, Berlin-Buch
          • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Volkmar Müller, Hamburg
          • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Christian Jackisch, Offenbach
          • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Dr. med. Hans-Christian Kolberg, Bottrop
          • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Sven Mahner, München
        • Statement Summary GIT-Cancers
        • Statements Colorectal Cancer
          • Statement Alexander Meisel, Zürich
        • Statements Gastric Cancer
          • Statement Alexander Meisel, Zürich
        • Statements Lung Cancer
        • Statement Renal Cell Carcinoma
      • Links to selected presentations and abstracts
        • Presidential Sessions
          • Presidential Session 1
          • Presidential Session 2
          • Presidential Session 3
        • Selection of Posters
          • 464P - Safety and efficacy of trifluridine/tipiracil (FTD/TPI) in metastatic colorectal cancer (mCRC) patients according to previous treatment with regorafenib in the international phase 3b PRECONNECT study
          • 1290P - Avelumab in European patients (pts) with metastatic Merkel cell carcinoma (mMCC): experience from an ad hoc expanded access program (EAP)
          • 509P - Factors influencing conversion to resectability and survival after resection of metastases in RAS WT metastatic colorectal cancer (mCRC): a FIRE-3 analysis
          • 481P - Phase II Study of Cetuximab Rechallenge in Patients with RAS Wild-Type metastatic Colorectal Cancer: E-Rechallenge Trial
          • 549P - Second line EGFR-inhibitors in RAS mutant metastatic colorectal cancer: the plasma RAS wild type “window of opportunity”
          • 1068P - Cetuximab in combination with methotrexate (MTX) as first-line treatment in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN), a phase Ib – randomized phase II study versus single agent MTX
    • Cancer Academy - Blut- und Lymphdrüsenkrebs
    • Comprehensive Cancer Center Zürich: Third Zurich Immuno-Oncology Symposium
      • Keynote address
      • Clinical results, patient cases and future developments I
      • Clinical results, patient cases and future developments II
      • Clinical results, patient cases and future developments III
      • Developments in immunotherapy
    • 20th World Congress on Gastrointestinal Cancer (WCGIC 2018)
      • Session I: Welcome with Selected Abstracts
      • Session II: Cancer of the Pancreas and Biliary Tract - Selected Abstracts
      • Session IV: Presentation of Selected Abstracts on Non-Colorectal Cancer
      • Pancreatic Cancer: Poster Session
      • Session VII: Gastric Cancer: Presentation of selected abstracts
      • Session VIII: Diseases and Cancers of the Liver: Presentation of a selected abstract
      • Session XI: Presentation of Selected Abstracts: Colorectal Cancer
      • Session XX: Colorectal Cancer: Presentation of selected abstracts
    • 23rd Congress of EHA
      • Presidential Symposium
      • Plenary Session Abstracts
      • Press Briefings
        • Press Briefing Day 1
        • Press Briefing Day 2
      • Important AML Presentations
        • IDHm and BCL2 inhibitors in AML
        • One AML Poster
      • Important CLL Presentations
      • Important Multiple Myeloma Presentations
        • Advances in front-line treatment of newly diagnosed multiple myeloma
        • New therapeutic strategies to improve the outcome of relapsed/refractory plasma cell disorders
        • Multiple Myeloma Poster Presentations
        • One Multiple Myeloma Late Breaking Abstract
      • Important Lymphoma Presentations
      • Thalassemia (2 Presentations) & MDS (1 Presentation)
    • ESMO Preceptorship on Colorectal Cancer 2018
    • SENOLOGIE update 2018
      • Prophylaktische Mastektomie - Moderation: M. Knauer, St. Gallen
      • Psychosoziale Konsequenzen des Mammakarzinoms - Moderation: E. Sarasin, Zürich
      • Update Systemtherapie - Moderation: U. Breitenstein, Zürich
      • Varia - Moderation: E. Saurenmann, Zürich
    • Cancer Academy - Darmkrebs
    • AACR Annual Meeting 2018, April 14-18,
      • Highlights presented at the Press Conference Sunday, April 15
      • Highlights presented at the Press Conference Monday, April 16
      • Highlights presented at the Press Conference Tuesday, April 17
    • ELCC 2018 (European Lung Cancer Congress)
      • Highlights - Press Releases
      • Interviews
        • Conference Highlights
        • Interviews in Cooperation with the Video Journal of Oncology - Part 1
      • SAKK 16/14 – Anti-PD-L1 antibody durvalumab (MEDI4736) in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC). A multicenter single-arm phase II trial.
    • 11th European Breast Cancer Conference (EBCC-11)
      • Press conferences
      • Important News
      • Interviews
        • PD Dr. med. Christian Kolberg, Bottrop
        • Prof. Dr. med. Thorsten Kühn, Esslingen
        • Prof. Dr. med. Nadia Harbeck, München
    • St. Gallen International Gastrointestinal Cancer Conference Primary Therapy of Early GI Cancers -
      • Session 1: Oesophago-Gastric Cancer: One Disease or Separate Entities?
      • Session 2: Treatment of Oesophago-Gastric Cancer: Setting the Stage – Who Benefits from Multimodal Therapy
      • Session 3: Treatment Modalities for Oesophago-Gastric Cancer
      • Session 4: Special situation I: Signet Ring Cell Cancer
      • Keynote: Hereditary Gastric Cancer
      • New Therapy Options by metastatic Colorectal Cancer
      • Session 5: Special situation II: Limits of Curative Approaches to Metastatic Oesophago-Gastric Cancer
      • Session 6: Ready for Practice?
      • EORTC Gastrointestinal Tract Cancer Group:
    • Cancer Academy - Prostatakrebs
    • Promoting Self-efficacy with Digital Tools
      • Welcome (German)
      • Promoting patients’ self-efficacy: How can it be successful? (German)
      • United Kingdom’s perspective on the use of digital solutions to improve cancer patients’ self-efficacy
      • Presentation of selected digital and patient-oriented applications
        • Consilium: Patient-centered communication for improved self-efficacy and quality of life
        • STREAM – Ein online Programm zur Unterstützung bei Belastung während einer Krebserkrankung
        • Symptom Navi: Förderung des Selbstmanagements von Symptomen bei Krebs
        • Entspannung und Achtsamkeit für Krebspatienten mit Hilfe einer App (CanRelax)
        • FertiOnco – an online approach to facilitate decision making in young female cancer patients regarding fertility preservation
      • The use of patient-reported outcomes to improve outcomes and quality in cancer care
      • Digital solutions for cancer patients: reach, (cost-) effectiveness and implementation
      • Discussion and Closing remarks (German)
  • Kongressberichte 2017
    • 59th ASH Annual Meeting and Exposition
      • Late-Breaking Abstracts Session
      • AML
        • Oral Sessions
          • Acute Myeloid Leukemia: Clinical Studies: Advances in Frontline Therapy: Induction, Consolidation, and Maintenance
          • Acute Myeloid Leukemia: Clinical Studies: Novel Therapies for AML and APL
          • Acute Myeloid Leukemia: Clinical Studies: Risk Factors and Response-Adapted Personalized Medicine
          • Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Emerging Molecularly-Targeted Therapies in AML
          • Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Novel Therapies for Elderly Patients with AML
          • Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Novel Targeted and Immune-based Approaches in the Treatment of AML
      • Multiple Myeloma
        • Oral Sessions
          • Myeloma: Therapy, excluding Transplantation: Upfront Therapy for Multiple Myeloma: Induction and Maintenance
          • Myeloma: Therapy, excluding Transplantation: Immunotherapy in Myeloma and Amyloid
          • Studies in Relapsed and Refractory Multiple Myeloma
          • Myeloma: Therapy, excluding Transplantation I
          • Myeloma: Therapy, excluding Transplantation II
        • Choice of Posters
      • Lymphoma
        • Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma
          • Clinical Studies: Mantle Cell Lymphoma, New Therapies
          • Indolent Lymphomas, Novel Therapies, and Diagnostics
          • Follicular Lymphoma, First Line
        • Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)
          • Novel Agents and Upfront Approaches
          • Immune-Based Therapeutic Approaches
        • Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)
          • Predicting Efficacy and Safety of CAR-T cells and Checkpoint Blockade
          • Outcomes in Rare Entities: HTLV-1 ATLL, Gray Zone Lymphoma, Primary CNS Lymphoma, and Intravascular DLBCL
          • Molecular Characterization of Diffuse Large B Cell Lymphoma
          • PET-Guided Therapy and Prognostic Models in Diffuse Large B-Cell Lymphoma
        • Hodgkin Lymphoma and T/NK Cell Lymphoma
          • Hodgkin Lymphoma Immunotherapy Studies; nodular lymphocyte predominant Hodgkin lymphoma clinical studies
          • Hodgkin Lymphoma—Chemotherapy and PET Studies
          • T-Cell Lymphoma Clinical Studies
        • CLL: Therapy, excluding Transplantation:
          • Targeting MRD Negative CLL Through Combinations of Novel Agents and Antibody
          • Targeting MRD Negative CLL with Combinations of Novel Agents and Chemoimmunotherapy Regimens, New Treatments
          • New Agents, Infections, and PET/CT
      • Press Conferences
        • Novel Approaches to Hemophilia and Venous Thromboembolism Care
        • Engineering Solutions to Treat Inherited Blood Disorders
        • Enhancing Care in Hematologic Malignancies through Targeted Therapies
        • Driving Outcomes in Lymphoma, Myeloma with CAR T-Cell Therapies
        • Late-Breaking Abstracts
      • Interviews
        • Statement Christian Taverna, Münsterlingen
        • Statement Thorsten Zenz, Zürich
    • 40th Annual San Antonio Breast Cancer Symposium (SABCS)
      • General Sessions
        • GENERAL SESSION 1:
        • GENERAL SESSION 2:
        • GENERAL SESSION 3:
        • GENERAL SESSION 4:
        • GENERAL SESSION 5:
        • GENERAL SESSION 6:
      • Press Conferences
        • Wednesday December 6 @ 7:15 a.m.
        • Wednesday December 6 @ 12:15 p.m
        • Thursday December 7 @ 7:30 am
        • Friday December 8 @ 7:30 am
      • Interviews & Brustkrebs Deutschland Round Table & SAKK Roundtable
        • Roundtable Brustkrebs Deutschland
        • Roundtable mit Experten aus der Schweiz
        • Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Dr. med. Hans-Christian Kolberg, Bottrop
        • Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Prof. Dr. med. Wolfgang Janni, Ulm
        • Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Prof. Dr. med. Christoph Thomssen, Halle-Saale
        • Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Prof. Dr. med. Christoph Thomssen, Halle-Saale
        • Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Prof. Dr. med. Christoph Thomssen, Halle-Saale
        • Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit  Prof. Dr. med. Peyman Hadji, Marburg
        • Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit  Prof. Dr. med. Peyman Hadji, Marburg
        • Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit  Prof. Dr. med. Michael Patrick Lux, Erlangen
        • Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit  Prof. Dr. med. Michael Patrick Lux, Erlangen
        • Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit  Prof. Dr. med. Cornelia Liedtke, Berlin
        • Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit  Prof. Dr. med. Cornelia Liedtke, Berlin (Kopie)
        • Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit  Prof. Dr. med. Stefan Buchholz, Regensburg
        • Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit  Prof. Dr. med. Thorsten Kühn, Esslingen
        • Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit  Dr. phil. Ute Berndt, Halle-Saale
        • Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Prof. Dr.med. Michael Untch, Berlin-Buch
    • Cancer Academy – Hirntumoren
    • 7. Interdisziplinäres Prostatakarzinomsymposium
      • Grundlagen
      • Lokalisiertes & oligometastatisches Prostatakarzinom
      • Systemtherapien Prostatakarzinom
    • Advanced Breast Cancer 4th ESO-ESMO International Consensus Conference
    • Cancer Academy – Brustkrebs
    • ESMO 2017 Congress
      • Breast Cancer Highlights
        • Neoadjuvante Therapie bei luminalem, triple negativem oder HER2 positivem Brustkrebs
        • Luminaler Brustkrebs - wer braucht Chemotherapie?
        • CDK4-6 Inhibitoren beim metastasierten Brustkrebs
        • Abstract LBA10_PR ‘Primary results of LORELEI: a phase II randomized, double-blind study of neoadjuvant letrozole (LET) plus taselisib versus LET plus placebo (PLA) in postmenopausal patients (pts) with ER+/HER2-negative early breast cancer (EBC)’
        • Abstract 1472P_PR ‘Change of patient perceptions of chemotherapy side effects in breast and ovarian cancer patients’
      • Gastrointestinal Carcinoma Highlights
        • Colorectal Cancer
          • Summary Statement
          • 593P - Quality of life (QoL) analyses in patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC) treated with first-line FOLFOX-4 ± cetuximab in the phase 3 TAILOR trial
          • Survival analysis of KRAS, NRAS, BRAF, PIK3CA wild type (wt) mCRC patients treated with FOLFIRI plus cetuximab in the CAPRI-GOIM trial
        • Gastric Cancer
      • Head & Neck Cancer Highlights
        • PD Dr. med. Sacha Rothschild comments Head&Neck Cancer Studies
        • Abstract LBA45_PR ‘Pembrolizumab (pembro) vs standard of care (SOC) for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): Phase 3 KEYNOTE-040 trial’
        • 1065P - 3-weekly or weekly cisplatin concurrently with radiotherapy for patients with locally advanced squamous cell carcinoma of the head and neck: A multicentre, retrospective analysis
        • 1. First line Cetuximab and Cisplatin with or without Paclitaxel/2. The observational ENCORE study: Cetuximab + platinum-based therapy
      • Lung Cancer Highlights
        • Prof. Martin Reck
        • PD Dr. AlessandraCurioni-Fontecedro
        • PD Dr. AlessandraCurioni-Fontecedro
        • Prof. Dr. med.Solange Peters
        • Alectinib: ALEX and ALUR trials show CNS benefit in NSCLC
      • Melanoma & Merkel Cell Carcinoma Highlights
        • Prof. Dr. med. Reinhard Dummer, Zurich
        • Prof. Dr. med. Olivier Michielin, Lausanne
      • Ovarian Cancer Highlights
      • Urogenital Cancer Highlights
        • Richard Cathomas, Chur, comments on the urogenital Carcinoma Highlights
        • Abstract LBA37_PR – ‘Pembrolizumab (pembro) versus paclitaxel, docetaxel, or vinflunine for recurrent, advanced urothelial cancer (UC): mature results from the phase 3 KEYNOTE-045 trial’
      • Late breaking news
        • Opening Press Conference
        • LBA Press Conference: Lung cancer
        • Press Conference: Facing the challenges of life after cancer
        • LBA Press Conference: Breast cancer, Gynaecological cancers, Genito-urinary cancers
        • LBA Press Conference: Melanoma cancer
        • Wrap-Up press conference/Best of ESMO2017
    • Cancer Center Zürich Second - Zurich Immuno-Oncology Symposium
      • Welcome
      • Essentials of tumour immunology and immunotherapies
      • Clinical results, patient cases and future developments I
      • Clinical results, patient cases and future developments II
      • Clinical results, patient cases and future developments III
      • Management of toxicities
    • ESMO 19th World Congress on Gastrointestinal Cancer
      • Cancer of the Pancreas
        • Session II: Cancer of the Pancreas & bile Ducts
        • Navigating Treatment Decisions in Metastatic Pancreatic Cancer, Presented by Prime Oncology
        • Optimizing the Continuum of Care for Patients with Pancreatic Cancer: A Case Study-Based Debate
        • Interview mit Prof. Gerald Prager, Wien
      • Colon Cancer Highlights
        • Session XIX: Colorectal Cancer
        • Prof. Dr. med. Bernhard Pestalozzi, UniversitätsSpital Zürich:
    • Die besonderen Bedürfnisse von Kindern und Jugendlichen mit Krebs
    • 14 The International Conference on Malignant Lymphoma (ICML)
      • Interviews & Introductory Press Conference
        • Introductory Press Conference
        • Lymphoma Therapy
        • Oncoletter Interviews in cooperation with VJHEMONC
      • Satellite Symposia
        • THE FIRST BIOSIMILAR RITUXIMAB BASED ON CLINICAL EVIDENCE
        • CHEMOTHERAPY IN INDOLENT LYMPHOMA - DYING OR WELL ALIVE?
    • ELCC 2017 Genf
    • Cancer Academy – Lungenkrebs: Früherkennung, Diagnose und Behandlung
    • SENOLOGIE update 2017
      • Radiologie - Moderation: F. Dammann, Zürich
      • Genetik - Moderation: R. Morant, Rapperswil
      • Qualitätssicherung in der Senologie - Moderation: C. Rageth, Zürich
      • Operative Therapie - Moderation: C. Tausch, Zürich
      • Das metastasierte Mammakarzionom - Moderation: A. Müller, Winterthur
      • Varia - Moderation: D. Fink, Zürich
    • 15th St.Gallen International Breast Cancer Conference
    • Symposium Thoracic Oncology – Guidelines and Beyond
      • Screening
      • Inquiring the molecular tumor characteristics
      • Shanghai meets Zürich
      • Treatment options in localized NSCLC
      • Multimodality approaches in rare thoracic tumors
      • Metastatic disease
 
Navigation überspringen

Navigation/Menu

 
Navigation überspringen
  • Kongressberichte 2021
    • 63rd ASH Annual Meeting and Exposition In-Person/Virtual
      • Late-Breaking Abstracts Session
      • Highlights of the Conference: Statements & Opinions
      • Press Briefing
        • COVID-19 Takes a Toll on People with Blood Cancers and Disorders
        • Studies Highlight Novel Approaches to Screening for and Treating Blood Disorders
      • ALL
        • Clinical and Epidemiological: Clinical, genetic and societal
        • Therapies, Excluding Transplantation and Cellular Immunotherapies I
        • Therapies, Excluding Transplantation and Cellular Immunotherapies II
      • AML
        • Acute Myeloid Leukemia: Clinical and Epidemiological
          • COVID and beyond
          • Outcomes and Omics Potpourri
          • Practice-changing studies
        • Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies
          • Innovative induction regimens in AML: data from real life and clinical trials
          • Current approach to FLT3 mutated AML
          • Updates in treatment for high-risk AML
        • Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies
          • Triplet Combinations of Novel Therapies
          • Targeted Therapies and Novel Therapies
      • Lymphoma
        • Mantle Cell, Follicular, and Other B-Cell Lymphomas
          • Targeted Therapy in Low Grade Lymphoma
          • Evolution of Immunotherapeutic Regimens in B-cell Lymphomas
          • Front-line Induction Therapy and Novel Agents After Relapse
          • Advances in Treatment Approaches
        • Hodgkin Lymphomas and T/NK cell Lymphomas
          • T/NK Cell Lymphoma Frontline Clinical Trials
          • Hodgkin Lymphoma Clinical Trials
          • T/NK Cell Lymphoma Relapsed Therapy
          • Hodgkin Lymphoma Clinical Outcomes Data
        • Aggressive Lymphomas Prospective Therapeutic Trials
          • Challenging Populations
          • Novel Agents and Combinations
        • Aggressive Lymphomas: Clinical and Epidemiological
          • Population data for Aggressive NHL Management
          • Clinical Management of Aggressive B cell NHL
          • Real World evidence for CAR-T Management I
          • Real World evidence for CAR-T Management II
      • CML
        • Mechanisms of resistance and expanded therapies
        • Progress with response prediction and TKI discontinuation
      • Myeloprolifertive Syndromes
        • Non-JAK inhibitor Therapies for Myelofibrosis Clinically Relevant Abstract
        • Risk Stratification and Prognostication Clinically Relevant Abstract
        • Transplantation, COVID-19 and Biology Insights Clinically Relevant Abstract
        • Novel Therapies for MPNs and JAK inhibitors for Myelofibrosis
      • MDS
        • Low Risk Myelodysplastic Syndrome Prognosis and Treatment
        • Treatment of High Risk Myelodysplastic Syndrome
        • Treatment of HIgh Risk and Relapsed/Refractory Myelodysplastic Syndrome
      • CLL
        • Combination Small Molecules
        • Clinical and Epidemiological I
        • Clinical and Epidemiological II
      • Multiple Myeloma
        • Multiple Myeloma and Plasma cell Dyscrasias: Clinical and Epidemiological
          • Monoclonal Gammopathies of Determined Significance: What We Have and What We Want
          • A Map for the Changing Landscape of Multiple Myeloma
          • Multiple Myeloma and Waldenstrom Macroglobulinemia: Exploring Biomarkers in the Era of Personalized Medicine
          • Reoptimizing Standards and Redefining Approaches
          • Challenges in Multiple Myeloma Therapy: Adopting New Approaches for Relapse and Monitor
        • Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials
          • Phase 2 and 3 Trials in Myeloma
          • Novel Targets and Amyloid
          • Treatment of NDMM and amyloidosis patients
          • Immune Therapy for Multiple Myeloma
      • Cellular Therapies
        • Cellular Therapies for Lymphomas
        • Cellular Therapies-Immune Interactions, Lineage Switching and CNS targets
        • Cellular Therapies for ALL
        • Cellular Therapies for Myeloma
        • Allogeneic CARs and CARs for T Cell Lymphomas
        • Cellular Therapies for Low and High Grade Lymphomas
        • Expanding Targets and Cellular Sources for Immunotherapies
    • 2021 SAN ANTONIO BREAST CANCER SYMPOSIUM
      • Interviews
        • Ingo Bauerfeind, Landshut
        • Nina Ditsch, Augsburg
        • Nadia Harbeck, München
        • Nadia Harbeck, München
        • Christian Jackisch, Offenbach
        • Wolfgang Janni, Ulm
        • Hans-Christian Kolberg, Bottrop
        • Thorsten Kühn, Esslingen
        • Michael Lux, Paderborn
        • Volkmar Müller, Hamburg
        • Volkmar Müller, Hamburg
        • Christoph Thomssen, Halle (Saale).
        • Michael Untch, Berlin-Buch
        • Michael Untch, Berlin-Buch
        • Mathias Warm, Köln-Holweide.
        • Achim Wöckel, Würzburg
        • Rachel Würstlein, München
      • General Session 1
      • General Session 2
      • General Session 3
      • General Session 4
    • 9. Interdisziplinäres Prostatakarzinom-Symposium
    • Swiss Oncology & Hematology Congress (SOHC)
    • Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie
      • Kongress-Pressekonferenz
      • Ausgewählte Abstracts
        • COVID-19 und Krebs
        • Hämatologie
          • Multiples Myelom I
          • Multiples Myelom III
          • Multiples Myelom IV
          • Akute myeloische Leukämie I
          • Akute myeloische Leukämie II
          • Akute myeloische Leukämie III
          • Indolente Lymphome/CLL/Hodgkin-Lymphome I
          • Indolente Lymphome/CLL/Hodgkin-Lymphome II
          • Chronische myeloische Leukämie
          • Aggressive Lymphome/Akute lymphatische Leukämie II
        • Onkologie
          • Lungenkarzinom (inkl. Pleura) I
          • Lungenkarzinom (inkl. Pleura) II
          • Lungenkarzinom (inkl. Pleura) III
          • Sarkome/Seltene Tumore
          • Nierenzellkarzinom
          • Prostata-/Urothel-/Keimzell-Tumoren
          • Hepatobiläres Karzinom/Pankreas-Karzinom
          • Gastrointestinale Tumoren
          • Mammakarzinom/ Gynäkologische Malignome (Ovar, Uterus)
    • ESMO Congress 2021
      • Interviews
        • Interviews - Brustkrebs
          • Renate Haidinger, Brustkrebs Deutschland e.V. im Interview mit Hans-Christian Kohlberg, Bottrop
          • Renate Haidinger, Brustkrebs Deutschland e.V. im Interview mit Wolfgang Janni, Ulm
          • Renate Haidinger, Brustkrebs Deutschland e.V. im Interview mit Volkmar Müller, Hamburg
          • Renate Haidinger, Brustkrebs Deutschland e.V. im Interview mit Christoph Thomssen, Halle-Saale
          • Renate Haidinger, Brustkrebs Deutschland e.V. im Interview mit Christoph Thomssen, Halle-Saale
          • Renate Haidinger, Brustkrebs Deutschland e.V. im Interview mit Michael Untch, Berlin-Buch
          • Renate Haidinger, Brustkrebs Deutschland e.V. im Interview mit Michael Untch, Berlin-Buch
      • Friday, September 17
        • Proferred Paper Sessions
          • Genitourinary tumours, non-prostate 1
          • Non-metastatic NSCLC and other thoracic malignancies
          • Gynaecological cancers
          • Investigational immunotherapy
          • Breast cancer, early stage
          • Developmental therapeutics
        • Mini oral sessions 
          • Gastrointestinal tumours, non-colorectal
          • Investigational immunotherapy
          • Head and neck cancer, excl. thyroid
          • Supportive and palliative care
          • Sarcoma
          • Translational research
      • Saturday, September 18
        • Presidential symposium 1
        • Proffered Paper sessions
          • NSCLC, metastatic 1
          • Gastrointestinal tumours, colorectal
          • Genitourinary tumours, prostate
          • Melanoma and other skin tumours
          • Basic science
        • Mini oral sessions
          • Breast cancer, metastatic
          • Genitourinary tumours, non-prostate
          • Non-metastatic NSCLC and other thoracic malignancies
          • Gastrointestinal tumours, colorectal
          • Public policy
      • Sunday, September 19
        • Presidential symposium 2
        • Proffered Paper sessions
          • Breast cancer, metastatic
          • Genitourinary tumours, non-prostate 2
          • CNS tumours
          • Gastrointestinal tumours, non-colorectal
          • Translational research
        • Mini oral sessions
          • NSCLC, metastatic
          • Genitourinary tumours, prostate
          • Haematological malignancies
          • Basic science
          • Gynaecological cancers
      • Monday, September 20
        • Presidential symposium 3
        • Proffered Paper sessions
          • Head and neck cancer, excl. thyroid
          • Gastrointestinal tumours, colorectal 2
          • Haematological malignancies
          • NSCLC, metastatic 2
          • Public policy
        • Mini oral sessions
          • Breast cancer, early stage
          • Melanoma and other skin tumours
          • Developmental therapeutics
          • CNS tumours
          • NETs and endocrine tumours
      • Tuesday, September 21
        • Proffered Paper sessions
          • Sarcoma
          • NETs and endocrine tumours
          • Supportive and palliative care
          • SARS-CoV-2 and cancer
        • Mini oral session
    • 18th International Myeloma Workshop
      • Thursday, September 9
        • Oral Abstract Sessions
        • Oral Abstract Sessions
      • Friday, September 10
        • Oral Abstract Sessions
        • Oral Abstract Sessions
      • Saturday, September 11
        • Oral Abstract Sessions
    • Innovative Software-Lösung entlastet die Ärzteschaft in der Onkologie
    • ESMO World Congress on Gastrointestinal Cancer 2021
      • Session I:
      • Session II:
      • Session IV:
      • Session V:
      • Session VI:
      • Session VII:
      • Session VIII:
      • Session IX:
      • Session X:
    • International Conference on Malignant Lymphoma (ICML)
      • PLENARY SESSION
      • SESSION 1:
      • SESSION 2:
      • SESSION 3:
      • SESSION 4:
      • SESSION 5
      • SESSION 6:
      • SESSION 7:
      • SESSION 8:
      • SESSION 9:
      • SESSION 10:
      • SESSION 11:
      • SESSION 12:
      • SESSION 13:
    • EHA2021 Virtual Congress
      • Presidential Symposium
      • Late-Breaking Oral Session
      • Acute leukemia
        • ALL - CAR-T: Alternative targets and age groups
        • ALL - Novel subgroups and agents
        • Developments in AML therapy
      • Chronic myeloid malignancies
        • Response, resistance and treatment-free remission in CML
        • Population based studies in myeloid disorders
        • Novel targets in MDS
        • New pathways and molecular mechanisms in MPN
        • Novel therapies and targets in MPN
      • Chronic lymphoid malignancies
        • Clinical trials with targeted therapies in CLL
        • New treatment strategies for newly diagnosed multiple myeloma
        • New diagnostic and therapeutic approaches in multiple myeloma and AL amyloidosis
        • T cell re-directing therapies in relapsed/refractory multiple myeloma
      • Lymphoma
        • Hodgkin lymphoma - Clinical
        • Indolent & mantle cell lymphoma - Clinical
        • Aggressive lymphoma - CAR-T & transplant
        • Aggressive lymphoma - Combination therapies
      • Immunology
        • Cellular immunotherapy and gene therapy - Clinical
        • Fungal, bacterial and viral infections in hematology
      • Red & white cell disorders
        • New directions in aplastic anemia and PNH
        • Stem cell transplantation - GvHD
        • Stem cell transplantation - Clinical
        • Changing the scene on sickle cell disease
        • Changing the scene on thalassemias
    • 2021 ASCO Annual Meeting
      • Plenary Session (LBA's) & Presscast Presentations
      • Breast Cancer
        • Interviews
          • Früher Brustkrebs neoadjuvant: Talazoparib bei triple-negativer BRCA 1/2 Keimbahnmutation
          • #ASCO21: WSG-ADAPT HR+/HER2- Ergebnisse in der Hochrisikogruppe
          • #ASCO21: Neoadjuvante De-Eskalation in WSG-ADAPT HR-/HER2+
          • #ASCO21: Olaparib nach (neo)adjuvanter Chemotherapie bei Keimbahnmutation BRCA 1/2
          • #ASCO21: Bedeutung der CSF ctDNA beim triple-negativen Brustkrebs (neoadjuvant)
          • #ASCO21: GeparNUEVO - neoadjuvant Durvalumab beim triple-negativen Brustkrebs
          • #ASCO21: Highlights zum metastasierten Brustkrebs
          • #ASCO21: Patientenumfrage zur Dosisanpassung beim metastasierten Brustkrebs
          • #ASCO21: Brustkrebs Highlights local/regional/adjuvant
          • #ASCO21: Metastasierter hormonpositiver Brustkrebs - Update zu den CDK4/6 Inhibitoren
        • Breast Cancer—Local/Regional/Adjuvant
        • Breast Cancer—Local/Regional/Adjuvant
        • Breast Cancer—Metastatic
        • Breast Cancer—Metastatic
      • Gastrointestinal Cancer
        • Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
        • Gastrointestinal Cancer—Colorectal and Anal
        • Gastrointestinal Cancer—Colorectal and Anal
        • Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
      • Gynaecological Cancer
        • Gynecologic Cancer
        • Gynecologic Cancer
      • Haematological Malignancies
        • Hematologic Malignancies—Plasma Cell Dyscrasia
        • Hematologic Malignancies—Plasma Cell Dyscrasia
        • Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
        • Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
        • Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
        • Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
      • Head & Neck Cancer
        • Head and Neck Cancer
        • Head and Neck Cancer
      • Lung Cancer
        • Lung Cancer—Non-Small Cell Metastatic
        • Lung Cancer—Non-Small Cell Metastatic
        • Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
        • Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
      • Melanoma/Merkel cell carcinoma
      • Urogenital Cancer
        • Genitourinary Cancer—Kidney and Bladder
        • Genitourinary Cancer—Kidney and Bladder
        • Genitourinary Cancer—Prostate, Testicular, and Penile
        • Genitourinary Cancer—Prostate, Testicular, and Penile
    • American Association for Cancer Research (AACR) Annual Meeting 2021
      • Important Papers presented at the Press Conference
      • Important Papers presented in Press Releases
    • ELCC 2021
    • 47th Annual Meeting of the European Society for Blood and Marrow Transplantation
      • Choice of oral Sessions
        • CART-T Cells 1
        • CART-T Cells 2
        • Multiple Myeloma
      • Choice Educational Sessions
        • CAR-T Toxicity and Management
        • CARs in Childhood Malignancy
        • New developments in the field of CAR cell therapy
      • Satellite Symposia
        • Present and future approaches with CAR T cell therapy in B-cell malignancies
        • Targeting the immune system in multiple myeloma: CAR T cell therapy and beyond
    • Brustkrebsinfotag 2021
    • News der Leitlinienkommission der AGO Mamma 2021
    • 2nd Zurich Brain Metastasis Symposium
      • Experimental Studies
      • Keynote Lectures
      • Updates on Therapeutic Approaches
      • Brain Metastasis: Disease Updates
      • Controversies & Hot Topics in the Diagnosis and Management of CNS Metastasis
    • Second Zurich Lung Cancer Symposium
      • Lung Cancer Screening and Approach to Small Lesions
      • Molecular Pathology of Lung Cancer
      • Development in Stage III NSCLC Disease
      • The Improvement of Survival in Metastatic NSCLC
      • The Importance of Clinical Trials
      • Approach to Oligometastatic Disease
    • 4th Zurich Immuno-Oncology Symposium
      • Keynote Address
      • Therapeutic Developments I
      • Therapeutic Developments II
      • Challenges in Patient Management
      • Challenges in Optimizing Treatment
      • Cell-based Therapies
    • Cancer Academy – Immuntherapie
    • First Zürich Precision Oncology Symposium
      • Speakers
      • Molecular Testing and Molecular Tumor Board
      • Keynote address
      • Precision Oncology for Solid Tumors 1/Ongoing Research Activities 1
      • Precision Oncology for Solid Tumors 2
      • Precision Oncology for Hematologic Malignancies
      • Precision Oncology for Solid Tumors 2/Ongoing Research Activities 2
  • Kongressberichte 2020
    • 2020 San Antonio Breast Cancer Virtual Symposium
      • Press Briefing
      • Interviews geführt von Renate Haidinger, Brustkrebs Deutschland e.V.
        • Interview mit Ingo Bauerfeind, Landshut
        • Interview mit Nadia Harbeck, München
        • Interview mit Christian Jackisch, Offenburg
        • Interview mit Wolfgang Janni, Ulm
        • Interview mit Wolfgang Janni, Ulm
        • Interview mit Michael Patrick Lux, Würzburg
        • Interview mit Volkmar Müller, Hamburg
        • Interview mit Volkmar Müller, Hamburg
        • Interview mit Christoph Thomssen, Halle (Saale)
        • Interview mit Michael Untch, Berlin-Buch
        • Interview mit Michael Untch, Berlin-Buch
        • Interview mit Achim Wöckel, Würzburg
        • Interview mit Achim Wöckel, Würzburg
      • General Sessions
        • GENERAL SESSION 1:
        • GENERAL SESSION 2:
        • GENERAL SESSION 3:
        • GENERAL SESSION 4:
    • All-Virtual 62nd ASH Annual Meeting and Exposition
      • Press Briefings
        • Press Briefing on Disparities in Health Care: Diversity, Equity, and Inclusion (DEI)
        • Press Briefing on What’s on the Horizon: Practice-Changing Clinical Trials
        • Press Briefing on Hematologic Aspects of the Pandemic: Advancing the Study of COVID-19
        • Press Briefing on Advancing New Frontiers: Genome Editing & Cellular Therapy
        • Press Briefing on Selected Late-Breaking Abstracts
      • Plenary Scientific Session
      • Late-Breaking Abstracts Session
      • Choice of two Scientific Workshops on Lymphoid Malignancies
        • Scientific Workshop on Tumor Immune Interactions
        • Scientific Workshop on Tumor Immune Interactions
      • Satellite Symposia
        • Exploring Antibody Therapy in ALL: How and Why to Integrate Antibody-Based Treatment Into Patient Management
        • Medical Crossfire®:Exploring the Modern Management of Acute Lymphoblastic Leukemia from AYA to Adult
        • A Fresh Look at CAR T-Cell Therapy: Recent Advances, New Evidence, and Evolving Paradigms to Improve Patient Care
      • Oral Sessions
        • Hemoglobinopathies
          • Hydroxyurea for Sickle Cell Disease
          • Sickle Cell Disease
          • Sickle Cell Disease
        • Coagulation & Platelet Disorders
          • Disorders of Platelet Number or Function
          • Disorders of Platelet Number or Function
        • Acute Lymphoblastic Leukemia
          • ALL - Clinical Studies
          • ALL - Clinical Studies
          • ALL - Therapy, excluding Transplantation
          • ALL - Therapy, excluding Transplantation
          • Choice of Posterpresentations with Pegaspargase
        • Acute Myeloid Leukemia
          • AML
          • AML
          • AML
          • AML
          • AML
          • AML - Novel Therapy, excluding Transplantation I
          • AML - Novel Therapy, excluding Transplantation II
          • AML - Novel Therapy, excluding Transplantation III
          • AML - Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis I
          • AML - Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis II
          • AML - Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis III
        • Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma
          • Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma
          • Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma
          • Mantle Cell and Indolent B-Cell Lymphoma
        • Hodgkin Lymphoma and T/NK Cell Lymphoma
          • Hodgkin Lymphoma and T/NK Cell Lymphoma
          • Hodgkin Lymphoma and T/NK Cell Lymphoma
          • Hodgkin Lymphoma and T/NK Cell Lymphoma
        • Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)
          • Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)
          • Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)
          • Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)
          • Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)
          • Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)
        • Chronic Myeloid Leukemia
          • Chronic Myeloid Leukemia
          • Chronic Myeloid Leukemia
        • Myeloproliferative Syndromes
          • Myeloproliferative Syndromes
          • Myeloproliferative Syndromes
          • Myeloproliferative Syndromes
        • Myelodysplastic Syndromes
          • Myelodysplastic Syndromes
          • Myelodysplastic Syndromes
        • CLL
          • CLL
          • CLL
        • Myeloma/Amyloidosis: Therapy excluding Transplantation:
          • Myeloma/Amyloidosis: Therapy excluding Transplantation
          • Myeloma/Amyloidosis: Therapy excluding Transplantation
          • Myeloma/Amyloidosis: Therapy excluding Transplantation
          • Myeloma/Amyloidosis: Therapy excluding Transplantation
          • Myeloma/Amyloidosis: Therapy excluding Transplantation
          • Myeloma/Amyloidosis: Therapy excluding Transplantation
    • 52th Congress of the International Society of Paediatric Oncology (SIOP)
      • Sessions Highlights
        • Wednesday
        • Thursday
        • Friday
        • Saturday
      • Building Bridges to ensure best possible outcomes for children and adults with ALL
    • DGHO, OeGHO, SGMO und SGH+SSH Jahrestagung 2020 VIRTUAL
      • Best Abstracts
      • Innovative Hämatologie
    • EBCC-12 European Breast Cancer Conference
    • ESMO VIRTUAL 2020
      • Presidential Symposia
        • Presidential Symposium I
        • Presidential Symposium II
        • Presidential Symposium III
      • Breast cancer
        • Interviews
        • Proffered Paper - Breast cancer, early stage
        • Proffered Paper - Breast cancer, metastatic 1
        • Proffered Paper - Breast cancer, metastatic 2
      • Thoracic Cancer
        • Proffered Paper - Non-metastatic NSCLC and other thoracic malignancies
        • Proffered Paper - NSCLC metastatic 1
        • Proffered Paper - NSCLC metastatic 2
      • CNS- & Skin Tumours, NETs & Sarcoma
        • Proffered Paper - NETs
        • Proffered Paper - Sarcoma
        • Proffered Paper - CNS tumours
        • Proffered Paper - Melanoma and other skin tumours
      • GU Tumours
        • Proffered Paper - GU, non prostate 1
        • Proffered Paper - GU, non prostate 2
        • Proffered Paper - GU, prostate
      • Gynaecological Cancers
        • Proffered Paper 1 - Gynaecological cancers
        • Proffered Paper 2 - Gynaecological cancers
      • Head & Neck & GI Cancers
        • Proffered Paper - Head & Neck cancer
        • Proffered Paper - GI, colorectal
        • Proffered Paper - GI, non colorectal
      • Immunotherapy, Translational Research & Basic Science
        • Proffered Papers - Investigational immunotherapy
        • Proffered Papers - Developmental therapeutics
        • Proffered Papers - Basic Science
        • Proffered Papers - Translational research
      • SARS-CoV-2 & Cancer
        • Proffered Paper - SARS-CoV-2 and cancer 1
        • Proffered Paper - SARS-CoV-2 and cancer 2
      • Supportive & Palliative Therapy, Public Policy
        • Proffered Paper - Supportive and palliative care
        • Proffered Paper - Public Policy
      • ESMO VIRTUAL CONGRESS 2020
    • VIRTUAL EBMT 46th Annual Meeting 2020
      • CAR-based Cellular Therapy
        • ACUTE LYMPHOBLASTIC LEUKEMIA
        • LARGE B-CELL LYMPHOMA
        • NON-HODGKIN LYMPHOMA
        • MULTIPLE MYELOMA
        • SIDE EFFECTS
        • MISCELLANEOUS
    • IASLC 21st World Conference on Lung Cancer
    • The 22nd ESMO World Congress on Gastrointestinal Cancer - Virtual Congress
      • Session I: Cancer of the Pancreas and Biliary Tract
      • Session II: Hepatocellular Cancer
      • Session III: Esophageal and Gastric Cancer
      • Session IV: Gastrointestinal Stromal Tumors (GIST); Neuroendocrine Tumors (NET)
      • Session V: Molecular Screening; Imaging; Artificial Intelligence
      • Session VI: Colorectal Cancer I
      • Session VII: Colorectal Cancer II
      • Session IX: Rectal Cancer
    • Virtual Edition of the 25th Annual Congress of the European Hematology Association
      • Presidential Symposium
      • Plenary Session I
      • Plenary Session II
      • Late-Breaking Oral Session - available fromSaturday June 13 8.30 AM
      • Oral Sessions
        • Acute Leukemia
          • ALL:
          • AML:
        • Lymphoma
          • Aggressive Lymphomas
          • Hodgkin lymphoma - Clinical
          • Indolent and mantle-cell non-Hodgkin lymphoma:
        • Chronic Myeloid Neoplasms
          • CML clinical
          • MDS:
          • MPN (Myelofibrosis & Hypereosinophilic Syndrome)
        • Chronic Lymphoid Neoplasms
          • CLL:
          • Multiple Myeloma
        • Immunology
          • CART cells
          • Immunotherapy:
          • Stem cell transplantation:
        • Red & White Cell Disorders
          • Iron in focus
          • Sickle cell disease:
          • Thalassemia:
        • ITP:
      • Link to Satellite Session - Live Fri 12 Jun 17:30-18:30
      • e-Poster Presentations
    • ASCO20 Virtual Scientific Meeting
      • Studies presented at press briefings
        • Pre-Meeting Presentation
        • Press Briefing May 28
      • Plenary Session Abstracts
      • Oral Sessions
        • Breast Cancer I
        • Breast Cancer II
        • Brustkrebs Interviews
        • Gynecologic Cancer
        • Gynäkologische Karzinomata - Interviews
    • SAMO Virtual Workshop on COVID19:
    • Coronavirus/Brustkrebs
    • AGO MAMMAKARZINOM - State of the Art Meeting 2020
      • Keynote-Lecture: Fatima Cardoso
      • Vormittag 1
      • Vormittag 2
      • Nachmittag 1
      • Nachmittag 2
      • Interviews im Rahmen einer Kooperation von Oncoletter mit Brustkrebs Deutschland e.v.
        • Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Andreas Schneeweiss, Heidelberg, zum Thema:
        • Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Volkmar Müller, Hamburg und Wolfgang Janni, Ulm, zum Thema:
        • Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Diana Lüftner Berlin, zum Thema:
        • Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Christian Jackisch, Offenbach & Andreas Schneeweiss, Heidelberg, zum Thema:
        • Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Bernd Gerber, Rostock zum Thema:
        • Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Volkmar Müller und Ute-Susann Albert, Frankfurt, zum Thema:
        • Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Achim Rody, Lübeck, zum Thema:
        • Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Achim Wöckel, Würzburg und Christoph Thomssen, Halle zum Thema:
        • Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Michael Lux, Erlangen, zum Thema:
        • Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit David Krug, Kiel, zum Thema:
        • Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Christoph Thomssen, Halle, zum Thema:
        • Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Nina Ditsch, München, zum Thema:
        • Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Marc Thill, Frankfurt und Michael Untch, Berlin, zum Thema:
        • Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Tanja Fehm, Düsseldorf und Elmar Stickeler, Aachen, zum Thema:
        • Gespräch mit Kerstin Rhiem, Köln, zum Thema:
        • Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Jens Huober, Ulm, zum Thema:
        • Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Thorsten Kühn, Esslingen und Jens Uwe Blohmer, Berlin, zum Thema:
        • Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Hans H. Kreipe, Hannover, zum Thema:
        • Eva Schumacher-Wulf für Brustkrebs Deutschland im Gespräch mit Ingo Bauerfeind, Landshut und Nina Ditsch, München, zum Thema:
    • Ten Years of ETOP
    • SABCS - 42nd Annual San Antonio Breast Cancer Symposium
      • Press Conferences
        • Wednesday, Dec. 11
        • Thursday, Dec. 12
        • Friday, Dec. 13
      • General Sessions 1-6
        • GENERAL SESSION 1:
        • GENERAL SESSION 2:
        • GENERAL SESSION 3:
        • GENERAL SESSION 4:
        • GENERAL SESSION 5:
        • GENERAL SESSION 6:
      • Interviews - Breast Cancer
        • HER 2-positiver, metastasierter Brustkrebs: HER2CLIMB Studie mit Tucatinib
        • HER 2-positiver, metastasierter Brustkrebs: DESTINY-Breast01 Studie mit Trastuzumab Deruxtecan
        • HER 2-positiver Brustkrebs adjuvant: APHINITY Studie, 2. Zwischenanalyse
        • HER 2-positiver Brustkrebs adjuvant: ATEMPT Studie T-DM1 gegen Paclitaxel plus Trastuzumab
        • Einsatz von Capecitabine Neo/Adjuvant
        • GEPARX Studie: Denosumab im Vergleich zu zwei Nab-Paclitaxel Schemata - neoadjuvant
        • Immuncheckpoint-Inhibitoren: Durvalumab beim metastasierten BC und Pembrolizumab neoadjuvant und adjuvant bei TNBC
        • pCR bei neoadjuvanter Therapie mit Atezolizumab beim TNBC?
        • Neues zu CDK4/6 Inhibitoren (HR+ & HER2-)
        • Wenn der Brust-Tumor weg ist nach neoadjuvanter Therapie: Muss noch operiert werden?
        • Teil- oder Ganzbrustbestrahlung nach Brust erhaltender Therapie. Was für wen?
      • Schweizer Expertenrunde mit einigen Highlights vom SABCS:
      • Round Table mit Brustkrebs Deutschland e.V.
    • 61st ASH Annual Meeting and Exposition
      • Highlights of the Conference: Statements & Opinions
        • ALL
        • Multiples Myelom
        • Multiples Myelom
        • Lymphome
      • Press Briefings
        • Saturday, December 7:
        • Saturday, December 7:
        • Saturday, December 7:
        • Sunday, December 8:
        • Monday, December 9 (embargoed until Tuesday 7:30 AM EST):
      • Late Breaking Abstract Session
      • Acute Lymphoblastic Leukemia (excluding Transplantation)
        • Therapeutic Strategies
        • Novel Therapies
        • Clinical Studies - Choice of Poster-Abstracts with Asparaginase
        • CAR T Cells--Refining the Approach
        • Chemo Immuno and Targets--Improving Combinations in ALL
      • Acute Myeloid Leukemia (excluding Transplantation)
        • Clinical Studies: Non-Intensive Therapy
        • Intensive Upfront Chemotherapy
        • Treatment of Relapsed/Refractory Disease
        • Induction and Post-Remission Therapy
        • New Treatment Strategies
        • Novel Immunotherapeutics, Checkpoint Inhibitors, and BiTEs
        • Novel Targets and Combinations
      • Chronic Myeloid Leukemia: Therapy
        • Predictors of TKI Discontinuation and TFR Outcomes
        • Clinical Trials and Outcomes
        • Response Monitoring and Prognosis
      • Myeloproliferative Syndromes
        • Emerging and Novel Targeted Therapies
        • JAK Inhibitors and Combination Therapies
      • Myelodysplastic Syndromes
        • Combination Therapies
        • Targeting Gene Mutations in MDS
        • Lower-Risk MDS and CMML
        • SAKK POSTER
      • Myeloma: Therapy, excluding Transplantation
        • New Approaches in the Treatment of Relapsed/Refractory Plasma Cell Discrasias
        • Novelty in CAR T in Relapsed/Refractory Multiple Myeloma
        • Therapeutics Questions in Newly Diagnosed Myeloma
        • Improving the Outcomes of Newly Diagnosed Multiple Myeloma
        • Novel Therapy for Relapsed Myeloma
      • CLL (excluding Transplantation)
        • First Line Treatment
        • Combination and Novel Treatment
        • BTK Inhibitors and CAR T Cells in CLL
      • Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies
        • Follicular Lymphoma: Biomarkers and Clinical Trials
        • Clinical Trials in Waldestrom's Macroglobulinemia and Other Indolent B-cell Non-Hodgkin Lymphomas
        • Mantle Cell Lymphoma: Frontline and Relapsed Therapies
      • Hodgkin Lymphoma and T/NK Cell Lymphoma
        • Combination Chemotherapy and Biomarkers of Response in Hodgkin Lymphoma
        • Immunotherapy Approaches in Hodgkin Lymphoma
        • Novel Therapies in Peripheral T-cell Lymphomas
      • Aggressive Lymphoma (DLBC and Other Aggressive B-Cell Non-Hodgkin Lymphomas
        • Results from Prospective Clinical Trials: Optimizing Frontline Chemotherapy
        • Results from Prospective Clinical Trials: Results from CAR T-Cell Trials  
        • Novel Therapies in Relapsed/Refractory Disease
        • Results from Retrospective/Observational Studies: Population-Based Outcomes
        • Results from Retrospective/Observational Studies: Prognostic Markers
        • Results from Retrospective/Observational Studies: Cellular Therapies
      • Immunotherapies
        • Immunotherapies I
        • Immunotherapies II
    • Gene Therapy and Transfer
      • Advancing CAR T Cells: New Biology and Therapeutic Applications
      • Gene Therapies for Non-Malignant Disorders
    • CAR-T-Zell Therapie in der Schweiz
  • Kongressberichte 2019
    • 6th ICIS Expert Meeting on “Critical questions in immune thrombocytopenia in children and adults”
      • Welcome
      • Session 1
      • Session 2
      • Session 3
      • Session 4
    • 8. Interdisziplinäres Prostatakarzinom-Symposium 2019
      • I Grundlagen und Früherkennung
      • II Lokoregionäre Therapie des Prostatakarzinoms
      • III Aspekte der Systemtherapie des Prostatakarzinoms
    • Jahrestagung 2019 von DGHO, OeGHO, SGMO und SGH+SSH
      • Pressekonferenz
    • OnkoZentrum Zürich - Patientenforum 2019
    • ESMO 2019
      • Press Briefings
        • Opening Press Conference
        • Lung and gynaecological cancers
        • Breast cancer
        • Gastrointestinal and genitourinary cancers
      • SAKK Studien am ESMO 2019
      • Brustkrebs
      • Gastrointestinal Cancers
        • Metastatic Colorectal Cancer (mCRC)
        • More from BEACON CRC & TAILOR
        • Metastatic Gastric, Pancreatic & Biliary Cancer
      • Lung Cancer, Mesothelioma & Head and Neck Cancer
      • Melanoma
      • Ovarialkarzinom
    • Cancer Academy - Kopf-Hals-Tumore
    • IASLC 2019 World Conference on Lung Cancer (#WCLC19)
      • Interviews
      • Press Briefings
        • Saturday, September 7th Press Briefing
        • Sunday, Sept. 8th Press Briefing
        • Monday, Sept 9th (Presidential Symposium Press Briefing)
        • Tuesday, Sept 10th Press Briefing
    • ESMO World Congress on Gastrointestinal Cancer
      • Press Conferences (News being made available according embargo rules)
        • Wednesday, 3 July - Opening Press Conference
        • Thursday, 4 July - Key studies of the day
        • Friday, 5 July - Key studies of the day
      • Session II: Cancer of the Pancreas and Biliary Tract
      • Presentation of Selected GI Cancer Abstracts
      • Presentation of Selected Rectal Cancer Abstracts
      • Session VII: Gastric Cancer - Presentation of Selected Abstracts
      • Session XII: Presentation of Selected Abstracts: Emerging New or Combination Drugs in GI Cancer Part 1
      • Session XII: Presentation of Selected Abstracts: Emerging New or Combination Drugs in GI Cancer Part 2
      • Session XI: Presentation of Selected Abstracts: Colorectal Cancer - Part 1
      • Session XI: Presentation of Selected Abstracts: Colorectal Cancer - Part 2
      • Session XVI: Hepatocellular Cancer - Presentation of Selected Abstracts
      • Session XX: Colorectal Cancer (Part I) - Presentation of Selected Abstracts & Comments Roger von Moos and Thomas Winder
    • 15th International Conference on Malignant Lymphoma (ICML)
      • Introductory Press Conference
      • PLENARY SESSION
      • MULTIPLE MYELOMA: EVERY YEAR A NEW STANDARD?
      • HOW TO APPROACH CLL IN CLINICAL PRACTICE
      • THE MODERN APPROACH TO MANTLE CELL LYMPHOMA
      • MANTLE CELL LYMPHOMA
      • PET IMAGING
      • PEDIATRIC LYMPHOMA
      • RESULTS FROM SINGLE AGENT TRIALS
      • ONGOING TRIALS
      • DLBCL: CLINICAL DATA
      • CLL
      • TREATMENT WITH NOVEL ANTIBODIES
      • T-CELL LYMPHOMAS
      • CLL AND MORE
      • CHEMOTHERAPY-FREE STRATEGIES
      • NON-CLINICAL AND EARLY CLINICAL DATA WITH NEW COMBINATIONS
      • HIGH RISK LARGE B-CELL LYMPHOMAS
      • LYMPHOMA PATHOLOGY
      • HODGKIN LYMPHOMA
      • FOLLICULAR LYMPHOMA
      • EXTRANODAL LYMPHOMAS
      • NEW DATA ON T-CELL AND OTHER LYMPHOMAS
      • ADVANCES IN CAR T-CELL TREATMENT
      • NEW DRUG COMBINATIONS
      • INDOLENT NON-FOLLICULAR LYMPHOMA
    • 24th Congress of EHA
      • Presidential Symposium
      • Late-breaking oral presentations (6 best abstracts)
      • Important presentations at Press Briefings
        • Friday, June 14, 2019
        • Saturday, June 15, 2019
      • Indolent and mantle-cell non-Hodgkin Lymphoma - clinical
      • Aggressive lymphomas - New agents
      • Aggressive lymphomas - First line, combination therapy and real-life data - Aggressive non-Hodgkin lymphoma
      • Hodgkin lymphoma - clinical
      • Novel agents and therapies for CLL
      • New stratification and treatment approaches in ALL - including CAR T Cell therapy
      • Advances in the management of thalassemia
      • Immunotherapy in relapsed/refractory multiple myeloma
      • Novel strategies in multiple myeloma
      • Novel agents for newly diagnosed plasma cell dyscrasias
      • Myeloma and other monoclonal gammopathies - Clinical
      • New therapies in AML
      • Gene therapy, cellular immunotherapy and vaccination - Biology & translational research
      • Gene therapy, cellular immunotherapy and vaccination - Clinical
      • Update on clinical trials in MPN
      • New agents in MPN
    • Annual Meeting of the American Society of Clinical Oncology 2019
      • Press Briefings
        • May 15 Presscast
        • Press Briefing Saturday June 1:
        • Press Briefing Sunday June 2:
        • Press Briefing Monday June 3:
      • Breast Cancer
        • Breast Cancer News Interviews
          • Sind biosimilare Antikörper beim Brustkrebs genauso wirksam wie das Original?
          • Metastasierter HER2-positiver Brustkrebs
          • Immuntherapie bei Brustkrebs
          • MONALEESA 7: Überlebensvorteil für prämenopausale Frauen mit Ribociclib
          • Seltene Brustkrebsarten
          • Brustkrebs beim Mann
          • Lymphknotenbefall vor und nach neoadjuvanter Chemotherapie (transSENTINA 5)
          • T-DM1 neoadjuvant bei HER2-positivem Mammakarzinom (KRISTINE)
        • Breast Cancer News Aufzeichnung Live-Stream
        • Oral & Poster Presentations
      • Colon Cancer
        • Oral Presentations
        • Poster Presentations
      • Other gastrointestinal Cancer
        • Oral Presentations
        • Poster Presentations
      • Other Gynaecologic Cancers
      • Head & Neck Cancers
        • Oral Presentations
        • Poster Presentations
      • Lung Cancer
      • Hauttumore
      • Urogenital Cancers
        • Oral Presentations
        • Poster Presentations
      • Hematology
        • Multiple Myeloma & Myelofibrosis
        • Lymphoma & CLL
        • ALL
    • Senologie Update 2019
      • Teil 1:
      • Teil 2:
      • Teil 3:
      • Teil 4:
    • ELCC 2019 - European Lung Cancer Congress | ESMO 10-13 April 2019 Geneva, Switzerland
    • BCC2019
      • Opening and Award Ceremony:
      • Session 1: News since St.Gallen 2017
      • Session 2: Biology of Breast Cancer I: Risk stratification
      • Session 3: Biology of breast cancer II: Prediction of response
      • Session 4: Risk stratification and prevention in ductal in situ carcinoma
      • Special lecture I and II
      • Session 5: New pathways with potential impact in the treatment of early breast cancer
      • Session 6: Treatment tailoring according to pathology and biology
      • Session 7: Surgery of early breast cancer
      • Session 8: Radiotherapy of early breast cancer
      • Special lecture III
      • Session 9: Primary and adjuvant systemic therapy of early breast cancer: Estimating the magnitude of clinical benefit I
      • Session 10: Primary and adjuvant systemic therapy of early breast cancer: Estimating the magnitude of clinical benefit II
      • GenomicHealth interactive satellite symposium in conjunction with the 16th St Gallen International Breast Cancer Conference
      • Nanostring Satellite Symposium: Recent Breakthroughs for HR+/HER2- Early Breast Cancer Patients:
      • Interviews (in German): Renate Haidinger, Brustkrebs Deutschland e.V. im Gespräch
      • Three SAKK Posters
    • 45th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)
      • Interviews
      • Presidential Symposium
        • GS2-2 - IMPROVED SURVIVAL OF AML- AND MDS-PATIENTS AFTER TREOSULFAN-BASED COMPARED TO REDUCED‑INTENSITY BUSULFAN-BASED CONDITIONING-REGIMEN FOR ALLOGENEIC HAEMATOPOIETIC CELL TRANSPLANTATION: FINAL RESULTS OF A PROSPECTIVE RANDOMISED PHASE-III-TRIAL
        • GS2-3 - GRAFT-VERSUS-LEUKEMIA EFFECT AFTER HAPLO-IDENTICAL STEM-CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE IN AML- NO ASSOCIATION WITH GRAFT-VERSUS-HOST-DISEASE: A STUDY OF THE ACUTE LEUKEMIA WORKING PARTY OF EBMT
        • GS2-4 - SEQUENTIAL CD19- AND CD22-CART CELL THERAPIES FOR RELAPSED B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: 10-MONTH MEDIAN FOLLOW-UP
        • GS2-5 - ALLOGENEIC STEM CELL TRANSPLANTATION FROM HAPLOIDENTICAL DONORS VERSUS MATCHED OR MISMATCHED 9/10 UNRELATED DONORS IN ACUTE LYMPHOBLASTIC LEUKEMIA IN FIRST COMPLETE REMISSION
        • GS2-6 - LOW-DOSE INFUSIONS OF CD45RA DEPLETED DONOR LYMPHOCYTES AFTER
 TCR ALPHA/BETA-DEPLETED TRANSPLANTATION IN PATIENTS WITH NON-MALIGNANT DISORDERS
        • GS2-7 - CELL-MEDIATED IMMUNOGENICITY OF THE ADJUVANTED RECOMBINANT ZOSTER VACCINE (RZV) IN ADULT AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS: A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED ZOE-HSCT CLINICAL TRIAL
      • Oral Session 9: Late-breaking abstracts
        • OS9-1 - COMPARABLE OUTCOME AFTER 10/10 AND 9/10 HLA-MATCHED UNRELATED DONOR STEM CELL TRANSPLANTATION (HSCT) USING POST-TRANSPLANT CYCLOPHOSPHAMIDE (PTCY) FOR GVHD PROPHYLAXIS, ON BEHALF OF THE ALWP-EBMT.
        • OS9-2 - MYELOABLATIVE CONDITIONING FOR FIRST ALLOGENEIC HSCT IN PEDIATRIC ALL: FTBI OR CHEMOTHERAPY? - AN UPDATE OF THE RETROSPECTIVE MULTICENTER EBMT-PDWP STUDY
        • OS9-3 - THE DETECTION OF THE SOLUBLE EBV ZEBRA PROTEIN AS A NEW PREDICTIVE BIOMARKER FOR PTLD
        • OS9-4 - EFFECTIVE CANCER IMMUNOTHERAPY WITH ERBB2-CAR-ENGINEERED CYTOKINE-INDUCED KILLER (CIK) CELLS IN HIGH-RISK SOFT TISSUE SARCOMAS
        • OS9-5 - GENESIS - A PHASE III RANDOMIZED DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, EVALUATING SAFETY AND EFFICACY OF BL-8040 AND G-CSF IN MOBILIZATION OF HCS´S FOR AUTOLOGOUS TRANSPLANTATION-MULTIPLE MYELOMA
        • OS9-6 - REAL LIFE EXPERIENCE IN THE TREATMENT OF PEDIATRIC, ADOLESCENT AND YOUNG ADULT ALL PATIENTS USING COMMERCIALLY AVAILABLE CAR-T-CELLS
      • How Do I... manufacture T cells for cellular therapies
        • HDI1-1 - Manufacturing of virus-specific T cells at an academic center
        • HDI1-2 - CAR T manufacturing in an academic setting
        • HDI1-3 - Low-dose memory T cell DLI for infection prophylaxis
      • How Do I... manage patients after CAR T-cell therapy.
        • HDI8-1 - Lymphoma, CLL and ALL
        • HDI8-2 - Myeloma patients
        • HDI8-3 - From a nurse's perspective
      • New developments in the field of CAR cell therapy
        • P2-1 - State of the art for ex-vivo manufactured autologous CAR T-cells
        • P2-2 - Simultaneous targeting of CD19 and CD22 with a bicistronic CAR - preliminary results of the AMELIA study
        • P2-3 - Off-the-shelf CAR NK cells for the treatment of hematologic malignancies
        • P2-4 - CAR T-cells against solid tumors: TRUCKs on the road
    • AGO MAMMAKARZINOM - State of the Art Meeting 2019
      • Vormittag 1
      • Vormittag 2
      • Nachmittag 1
      • Nachmittag 2
      • Interviews: Renate Haidinger, Brustkrebs Deutschland e.V. im Gespräch
  • Kongressberichte 2018
    • SABCS - 41st Annual San Antonio Breast Cancer Symposium
      • Press Conferences
        • Wednesday, Dec. 5, Press Conference 1
        • Wednesday, Dec. 5, Press Conference 2
        • Thursday, Dec. 6 Press Conference
        • Friday, Dec. 7 Press Conference
      • Schweizer Poster am SABCS
      • Interviews - Breast Cancer
        • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Christian Jackisch, Offenbach
        • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Michael Untch, Berlin-Buch
        • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Michael Patrick Lux, Erlangen
        • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Achim Rody, Lübeck
        • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Nadia Harbeck, München:
        • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Nadia Harbeck, München:
        • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Volkmar Müller, Hamburg
        • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Christoph Thomssen, Halle/Saale
        • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Cornelia Liedtke, Berlin
        • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Priv.-Doz. Dr. med. Hans-Christian Kolberg in Bottrop
        • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Thorsten Kühn, Esslingen
        • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Michael Wilhelm Braun, München
        • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Wolfgang Janni, Ulm
        • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Wolfgang Janni, Ulm
        • Dr. Petra Ortner, JOURNAL ONKOLOGIE im Gespräch mit Prof. Dr. med. Sibylle Loibl, Frankfurt
        • Dr. Petra Ortner, JOURNAL ONKOLOGIE im Gespräch mit Prof. Dr. med. Michael Untch, Berlin-Buch
        • Dr. Petra Ortner, JOURNAL ONKOLOGIE im Gespräch mit Dr. Rachel Würstlein, München
        • Dr. Petra Ortner, JOURNAL ONKOLOGIE im Gespräch mit Dr. med. Jörg Schilling, Berlin
        • Dr. Petra Ortner, JOURNAL ONKOLOGIE im Gespräch mit Priv.-Doz. Dr. med. Hans-Christian Kolberg, Bottrop
        • Dr. Petra Ortner, JOURNAL ONKOLOGIE im Gespräch mit Dr. med. Lothar Müller, Onkologie Unterems
      • Schweizer Expertenrunde mit einigen Highlights vom SABCS:
      • Round Table mit Brustkrebs Deutschland e.V.
      • General Sessions
        • GENERAL SESSION 1:
        • GENERAL SESSION 2:
        • GENERAL SESSION 3:
        • GENERAL SESSION 4:
        • GENERAL SESSION 5:
        • GENERAL SESSION 6:
    • American Society of Hematology (ASH) 60th Annual Meeting and Exposition
      • Statements & Opinions from some Highlights of the Conference
        • PD Dr. med. Nicolas Bonadies, Bern
        • Prof. Dr. med. Christoph Driessen, St. Gallen
        • Prof. Dr. med. Christoph Renner, Zürich
      • Press Briefings
        • Saturday December 1
          • Improving Sickle Cell Disease Outcomes in the U.S. and Africa
          • Major Trials Show Benefits of New Therapy Regimens for Cancer and Blood Disorders
          • CAR T-Cell Therapies: New Research and Updates from Pivotal Trials
        • Sunday December 2
        • Monday December 3
          • Late-Breaking Abstracts - Non-Malignant
          • Late-Breaking Abstracts - Malignant
      • Late-Breaking Abstracts Session
      • Myeloma: Therapy and upfront autologous Transplantation
        • Novel Antibody Combinations in Myeloma
        • Novel Targeted Combinations in Myeloma
        • Antibodies and Targeted Therapies
        • Novel Proteasome Inhibitors
        • Immunotherapies in Plasma Cell Disorders
        • Immunotherapy
        • Upfront Autologous Transplantation
        • Choice of Myeloma Posters
      • AML
        • Acute Myeloid Leukemia - Clinical Studies
          • Immunotherapy and New Agents
          • Minimal Residual Disease and Genetic Characterization
          • Maintenance after Allogeneic Stem Cell Transplant and Management of Refractory/Relapsed AML
        • Acute Myeloid Leukemia - Commercially Available Therapy, excluding Transplantation:
          • Optimal Induction and Re-Induction Regimens For Acute Myeloid Leukemia
          • Targeted Therapy For Adults Diagnosed With Acute Myeloid Leukemia
        • Acute Myeloid Leukemia - Novel Therapy, excluding Transplantation
          • Combination Therapy
          • Targeted Therapy
          • New Treatment Strategies
          • Immunotherapy
      • Lymphoma
        • Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies
          • Prognostic Markers and Therapies in Mantle Cell Lymphoma and Waldenstrom's Macroglobulinemia
          • Novel Therapies and Prognostic Assessment in Hairy Cell Leukemia and Indolent Non-Hodgkin Lymphoma
          • Antibodies, Immunomodulators, and BTK Inhibitors in Indolent NHL
        • Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies
          • Immunotherapy and Targeted Strategies
          • Hodgkin Lymphoma: Chemotherapy and Response Adapted Approaches
          • T Cell Lymphoma: Chemotherapy and Targeted Approaches
        • Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Prospective Clinical Trials
          • Immunotherapy
          • New Agents
          • Initial Treatment
        • Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Retrospective/Observational Studies
          • Outcomes With CD19 CAR T Therapy and Checkpoint Blockade in the Real World Setting
          • Prognostic Biomarkers and Molecular Signatures for Risk Stratification
          • Population Based Outcomes in Aggressive Lymphoma
          • Outcomes Of Lymphoma In The Elderly
      • Acute Lymphoblastic Leukemia: Clinical Studies & Therapy Excluding Transplantations
        • Improving Outcomes with Cellular Therapy
        • Improving Frontline Therapy in ALL
        • Chimeric Antigen Receptor T-cell therapy in ALL: What Is Next?
        • Targeted Therapy in ALL: Immunotherapy and Beyond
      • CLL: Therapy, excluding Transplantation:
        • Measurable Residual Disease in CLL: Moving Towards a Cure
        • Cellular Therapy and Immunomodulation in CLL
        • Advances in CLL Using Novel Combination Therapy
      • Chronic Myeloid Leukemia: Therapy
        • Epidemiology, Prognosis, and Real Life Care
        • First Line Trials and Prognostic Factors of Treatment-Free Remission
        • TFR Failure, Resistance, and New Drug Development
      • Myelodysplastic Syndromes—Clinical Studies: Novel Therapeutics, Prognosis and Prediction
        • Novel Therapeutics I
        • Novel Therapeutics II
        • Prognosis and Prediction
      • Scientific, medical, clinical, relevant “asparaginase” related Presentations
      • Health Services & Outcome Research—Malignant Diseases
      • Clinical Trials for Hemophilia and Using CAR T Cells
      • Thalassemia and Globin Gene Regulation
    • Cancer Academy: Sarkome, Früherkennung, Diagnose und Behandlung
    • ESMO 2018 Congress
      • Press Briefings
        • Breast Cancer
        • Ovarian Cancer
        • Prostate & Kidney Cancers
        • Head & Neck Cancer
        • All ESMO 2018 Press Releases
      • Interviews
        • Interviews - Breast Cancer
          • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Michael Untch, Berlin-Buch
          • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Volkmar Müller, Hamburg
          • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Christian Jackisch, Offenbach
          • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Dr. med. Hans-Christian Kolberg, Bottrop
          • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Sven Mahner, München
        • Statement Summary GIT-Cancers
        • Statements Colorectal Cancer
          • Statement Alexander Meisel, Zürich
        • Statements Gastric Cancer
          • Statement Alexander Meisel, Zürich
        • Statements Lung Cancer
        • Statement Renal Cell Carcinoma
      • Links to selected presentations and abstracts
        • Presidential Sessions
          • Presidential Session 1
          • Presidential Session 2
          • Presidential Session 3
        • Selection of Posters
          • 464P - Safety and efficacy of trifluridine/tipiracil (FTD/TPI) in metastatic colorectal cancer (mCRC) patients according to previous treatment with regorafenib in the international phase 3b PRECONNECT study
          • 1290P - Avelumab in European patients (pts) with metastatic Merkel cell carcinoma (mMCC): experience from an ad hoc expanded access program (EAP)
          • 509P - Factors influencing conversion to resectability and survival after resection of metastases in RAS WT metastatic colorectal cancer (mCRC): a FIRE-3 analysis
          • 481P - Phase II Study of Cetuximab Rechallenge in Patients with RAS Wild-Type metastatic Colorectal Cancer: E-Rechallenge Trial
          • 549P - Second line EGFR-inhibitors in RAS mutant metastatic colorectal cancer: the plasma RAS wild type “window of opportunity”
          • 1068P - Cetuximab in combination with methotrexate (MTX) as first-line treatment in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN), a phase Ib – randomized phase II study versus single agent MTX
    • Cancer Academy - Blut- und Lymphdrüsenkrebs
    • Comprehensive Cancer Center Zürich: Third Zurich Immuno-Oncology Symposium
      • Keynote address
      • Clinical results, patient cases and future developments I
      • Clinical results, patient cases and future developments II
      • Clinical results, patient cases and future developments III
      • Developments in immunotherapy
    • 20th World Congress on Gastrointestinal Cancer (WCGIC 2018)
      • Session I: Welcome with Selected Abstracts
      • Session II: Cancer of the Pancreas and Biliary Tract - Selected Abstracts
      • Session IV: Presentation of Selected Abstracts on Non-Colorectal Cancer
      • Pancreatic Cancer: Poster Session
      • Session VII: Gastric Cancer: Presentation of selected abstracts
      • Session VIII: Diseases and Cancers of the Liver: Presentation of a selected abstract
      • Session XI: Presentation of Selected Abstracts: Colorectal Cancer
      • Session XX: Colorectal Cancer: Presentation of selected abstracts
    • 23rd Congress of EHA
      • Presidential Symposium
      • Plenary Session Abstracts
      • Press Briefings
        • Press Briefing Day 1
        • Press Briefing Day 2
      • Important AML Presentations
        • IDHm and BCL2 inhibitors in AML
        • One AML Poster
      • Important CLL Presentations
      • Important Multiple Myeloma Presentations
        • Advances in front-line treatment of newly diagnosed multiple myeloma
        • New therapeutic strategies to improve the outcome of relapsed/refractory plasma cell disorders
        • Multiple Myeloma Poster Presentations
        • One Multiple Myeloma Late Breaking Abstract
      • Important Lymphoma Presentations
      • Thalassemia (2 Presentations) & MDS (1 Presentation)
    • ESMO Preceptorship on Colorectal Cancer 2018
    • SENOLOGIE update 2018
      • Prophylaktische Mastektomie - Moderation: M. Knauer, St. Gallen
      • Psychosoziale Konsequenzen des Mammakarzinoms - Moderation: E. Sarasin, Zürich
      • Update Systemtherapie - Moderation: U. Breitenstein, Zürich
      • Varia - Moderation: E. Saurenmann, Zürich
    • Cancer Academy - Darmkrebs
    • AACR Annual Meeting 2018, April 14-18,
      • Highlights presented at the Press Conference Sunday, April 15
      • Highlights presented at the Press Conference Monday, April 16
      • Highlights presented at the Press Conference Tuesday, April 17
    • ELCC 2018 (European Lung Cancer Congress)
      • Highlights - Press Releases
      • Interviews
        • Conference Highlights
        • Interviews in Cooperation with the Video Journal of Oncology - Part 1
      • SAKK 16/14 – Anti-PD-L1 antibody durvalumab (MEDI4736) in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC). A multicenter single-arm phase II trial.
    • 11th European Breast Cancer Conference (EBCC-11)
      • Press conferences
      • Important News
      • Interviews
        • PD Dr. med. Christian Kolberg, Bottrop
        • Prof. Dr. med. Thorsten Kühn, Esslingen
        • Prof. Dr. med. Nadia Harbeck, München
    • St. Gallen International Gastrointestinal Cancer Conference Primary Therapy of Early GI Cancers -
      • Session 1: Oesophago-Gastric Cancer: One Disease or Separate Entities?
      • Session 2: Treatment of Oesophago-Gastric Cancer: Setting the Stage – Who Benefits from Multimodal Therapy
      • Session 3: Treatment Modalities for Oesophago-Gastric Cancer
      • Session 4: Special situation I: Signet Ring Cell Cancer
      • Keynote: Hereditary Gastric Cancer
      • New Therapy Options by metastatic Colorectal Cancer
      • Session 5: Special situation II: Limits of Curative Approaches to Metastatic Oesophago-Gastric Cancer
      • Session 6: Ready for Practice?
      • EORTC Gastrointestinal Tract Cancer Group:
    • Cancer Academy - Prostatakrebs
    • Promoting Self-efficacy with Digital Tools
      • Welcome (German)
      • Promoting patients’ self-efficacy: How can it be successful? (German)
      • United Kingdom’s perspective on the use of digital solutions to improve cancer patients’ self-efficacy
      • Presentation of selected digital and patient-oriented applications
        • Consilium: Patient-centered communication for improved self-efficacy and quality of life
        • STREAM – Ein online Programm zur Unterstützung bei Belastung während einer Krebserkrankung
        • Symptom Navi: Förderung des Selbstmanagements von Symptomen bei Krebs
        • Entspannung und Achtsamkeit für Krebspatienten mit Hilfe einer App (CanRelax)
        • FertiOnco – an online approach to facilitate decision making in young female cancer patients regarding fertility preservation
      • The use of patient-reported outcomes to improve outcomes and quality in cancer care
      • Digital solutions for cancer patients: reach, (cost-) effectiveness and implementation
      • Discussion and Closing remarks (German)
  • Kongressberichte 2017
    • 59th ASH Annual Meeting and Exposition
      • Late-Breaking Abstracts Session
      • AML
        • Oral Sessions
          • Acute Myeloid Leukemia: Clinical Studies: Advances in Frontline Therapy: Induction, Consolidation, and Maintenance
          • Acute Myeloid Leukemia: Clinical Studies: Novel Therapies for AML and APL
          • Acute Myeloid Leukemia: Clinical Studies: Risk Factors and Response-Adapted Personalized Medicine
          • Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Emerging Molecularly-Targeted Therapies in AML
          • Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Novel Therapies for Elderly Patients with AML
          • Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Novel Targeted and Immune-based Approaches in the Treatment of AML
      • Multiple Myeloma
        • Oral Sessions
          • Myeloma: Therapy, excluding Transplantation: Upfront Therapy for Multiple Myeloma: Induction and Maintenance
          • Myeloma: Therapy, excluding Transplantation: Immunotherapy in Myeloma and Amyloid
          • Studies in Relapsed and Refractory Multiple Myeloma
          • Myeloma: Therapy, excluding Transplantation I
          • Myeloma: Therapy, excluding Transplantation II
        • Choice of Posters
      • Lymphoma
        • Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma
          • Clinical Studies: Mantle Cell Lymphoma, New Therapies
          • Indolent Lymphomas, Novel Therapies, and Diagnostics
          • Follicular Lymphoma, First Line
        • Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)
          • Novel Agents and Upfront Approaches
          • Immune-Based Therapeutic Approaches
        • Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)
          • Predicting Efficacy and Safety of CAR-T cells and Checkpoint Blockade
          • Outcomes in Rare Entities: HTLV-1 ATLL, Gray Zone Lymphoma, Primary CNS Lymphoma, and Intravascular DLBCL
          • Molecular Characterization of Diffuse Large B Cell Lymphoma
          • PET-Guided Therapy and Prognostic Models in Diffuse Large B-Cell Lymphoma
        • Hodgkin Lymphoma and T/NK Cell Lymphoma
          • Hodgkin Lymphoma Immunotherapy Studies; nodular lymphocyte predominant Hodgkin lymphoma clinical studies
          • Hodgkin Lymphoma—Chemotherapy and PET Studies
          • T-Cell Lymphoma Clinical Studies
        • CLL: Therapy, excluding Transplantation:
          • Targeting MRD Negative CLL Through Combinations of Novel Agents and Antibody
          • Targeting MRD Negative CLL with Combinations of Novel Agents and Chemoimmunotherapy Regimens, New Treatments
          • New Agents, Infections, and PET/CT
      • Press Conferences
        • Novel Approaches to Hemophilia and Venous Thromboembolism Care
        • Engineering Solutions to Treat Inherited Blood Disorders
        • Enhancing Care in Hematologic Malignancies through Targeted Therapies
        • Driving Outcomes in Lymphoma, Myeloma with CAR T-Cell Therapies
        • Late-Breaking Abstracts
      • Interviews
        • Statement Christian Taverna, Münsterlingen
        • Statement Thorsten Zenz, Zürich
    • 40th Annual San Antonio Breast Cancer Symposium (SABCS)
      • General Sessions
        • GENERAL SESSION 1:
        • GENERAL SESSION 2:
        • GENERAL SESSION 3:
        • GENERAL SESSION 4:
        • GENERAL SESSION 5:
        • GENERAL SESSION 6:
      • Press Conferences
        • Wednesday December 6 @ 7:15 a.m.
        • Wednesday December 6 @ 12:15 p.m
        • Thursday December 7 @ 7:30 am
        • Friday December 8 @ 7:30 am
      • Interviews & Brustkrebs Deutschland Round Table & SAKK Roundtable
        • Roundtable Brustkrebs Deutschland
        • Roundtable mit Experten aus der Schweiz
        • Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Dr. med. Hans-Christian Kolberg, Bottrop
        • Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Prof. Dr. med. Wolfgang Janni, Ulm
        • Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Prof. Dr. med. Christoph Thomssen, Halle-Saale
        • Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Prof. Dr. med. Christoph Thomssen, Halle-Saale
        • Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Prof. Dr. med. Christoph Thomssen, Halle-Saale
        • Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit  Prof. Dr. med. Peyman Hadji, Marburg
        • Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit  Prof. Dr. med. Peyman Hadji, Marburg
        • Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit  Prof. Dr. med. Michael Patrick Lux, Erlangen
        • Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit  Prof. Dr. med. Michael Patrick Lux, Erlangen
        • Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit  Prof. Dr. med. Cornelia Liedtke, Berlin
        • Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit  Prof. Dr. med. Cornelia Liedtke, Berlin (Kopie)
        • Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit  Prof. Dr. med. Stefan Buchholz, Regensburg
        • Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit  Prof. Dr. med. Thorsten Kühn, Esslingen
        • Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit  Dr. phil. Ute Berndt, Halle-Saale
        • Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Prof. Dr.med. Michael Untch, Berlin-Buch
    • Cancer Academy – Hirntumoren
    • 7. Interdisziplinäres Prostatakarzinomsymposium
      • Grundlagen
      • Lokalisiertes & oligometastatisches Prostatakarzinom
      • Systemtherapien Prostatakarzinom
    • Advanced Breast Cancer 4th ESO-ESMO International Consensus Conference
    • Cancer Academy – Brustkrebs
    • ESMO 2017 Congress
      • Breast Cancer Highlights
        • Neoadjuvante Therapie bei luminalem, triple negativem oder HER2 positivem Brustkrebs
        • Luminaler Brustkrebs - wer braucht Chemotherapie?
        • CDK4-6 Inhibitoren beim metastasierten Brustkrebs
        • Abstract LBA10_PR ‘Primary results of LORELEI: a phase II randomized, double-blind study of neoadjuvant letrozole (LET) plus taselisib versus LET plus placebo (PLA) in postmenopausal patients (pts) with ER+/HER2-negative early breast cancer (EBC)’
        • Abstract 1472P_PR ‘Change of patient perceptions of chemotherapy side effects in breast and ovarian cancer patients’
      • Gastrointestinal Carcinoma Highlights
        • Colorectal Cancer
          • Summary Statement
          • 593P - Quality of life (QoL) analyses in patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC) treated with first-line FOLFOX-4 ± cetuximab in the phase 3 TAILOR trial
          • Survival analysis of KRAS, NRAS, BRAF, PIK3CA wild type (wt) mCRC patients treated with FOLFIRI plus cetuximab in the CAPRI-GOIM trial
        • Gastric Cancer
      • Head & Neck Cancer Highlights
        • PD Dr. med. Sacha Rothschild comments Head&Neck Cancer Studies
        • Abstract LBA45_PR ‘Pembrolizumab (pembro) vs standard of care (SOC) for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): Phase 3 KEYNOTE-040 trial’
        • 1065P - 3-weekly or weekly cisplatin concurrently with radiotherapy for patients with locally advanced squamous cell carcinoma of the head and neck: A multicentre, retrospective analysis
        • 1. First line Cetuximab and Cisplatin with or without Paclitaxel/2. The observational ENCORE study: Cetuximab + platinum-based therapy
      • Lung Cancer Highlights
        • Prof. Martin Reck
        • PD Dr. AlessandraCurioni-Fontecedro
        • PD Dr. AlessandraCurioni-Fontecedro
        • Prof. Dr. med.Solange Peters
        • Alectinib: ALEX and ALUR trials show CNS benefit in NSCLC
      • Melanoma & Merkel Cell Carcinoma Highlights
        • Prof. Dr. med. Reinhard Dummer, Zurich
        • Prof. Dr. med. Olivier Michielin, Lausanne
      • Ovarian Cancer Highlights
      • Urogenital Cancer Highlights
        • Richard Cathomas, Chur, comments on the urogenital Carcinoma Highlights
        • Abstract LBA37_PR – ‘Pembrolizumab (pembro) versus paclitaxel, docetaxel, or vinflunine for recurrent, advanced urothelial cancer (UC): mature results from the phase 3 KEYNOTE-045 trial’
      • Late breaking news
        • Opening Press Conference
        • LBA Press Conference: Lung cancer
        • Press Conference: Facing the challenges of life after cancer
        • LBA Press Conference: Breast cancer, Gynaecological cancers, Genito-urinary cancers
        • LBA Press Conference: Melanoma cancer
        • Wrap-Up press conference/Best of ESMO2017
    • Cancer Center Zürich Second - Zurich Immuno-Oncology Symposium
      • Welcome
      • Essentials of tumour immunology and immunotherapies
      • Clinical results, patient cases and future developments I
      • Clinical results, patient cases and future developments II
      • Clinical results, patient cases and future developments III
      • Management of toxicities
    • ESMO 19th World Congress on Gastrointestinal Cancer
      • Cancer of the Pancreas
        • Session II: Cancer of the Pancreas & bile Ducts
        • Navigating Treatment Decisions in Metastatic Pancreatic Cancer, Presented by Prime Oncology
        • Optimizing the Continuum of Care for Patients with Pancreatic Cancer: A Case Study-Based Debate
        • Interview mit Prof. Gerald Prager, Wien
      • Colon Cancer Highlights
        • Session XIX: Colorectal Cancer
        • Prof. Dr. med. Bernhard Pestalozzi, UniversitätsSpital Zürich:
    • Die besonderen Bedürfnisse von Kindern und Jugendlichen mit Krebs
    • 14 The International Conference on Malignant Lymphoma (ICML)
      • Interviews & Introductory Press Conference
        • Introductory Press Conference
        • Lymphoma Therapy
        • Oncoletter Interviews in cooperation with VJHEMONC
      • Satellite Symposia
        • THE FIRST BIOSIMILAR RITUXIMAB BASED ON CLINICAL EVIDENCE
        • CHEMOTHERAPY IN INDOLENT LYMPHOMA - DYING OR WELL ALIVE?
    • ELCC 2017 Genf
    • Cancer Academy – Lungenkrebs: Früherkennung, Diagnose und Behandlung
    • SENOLOGIE update 2017
      • Radiologie - Moderation: F. Dammann, Zürich
      • Genetik - Moderation: R. Morant, Rapperswil
      • Qualitätssicherung in der Senologie - Moderation: C. Rageth, Zürich
      • Operative Therapie - Moderation: C. Tausch, Zürich
      • Das metastasierte Mammakarzionom - Moderation: A. Müller, Winterthur
      • Varia - Moderation: D. Fink, Zürich
    • 15th St.Gallen International Breast Cancer Conference
    • Symposium Thoracic Oncology – Guidelines and Beyond
      • Screening
      • Inquiring the molecular tumor characteristics
      • Shanghai meets Zürich
      • Treatment options in localized NSCLC
      • Multimodality approaches in rare thoracic tumors
      • Metastatic disease
 
Startseite Kongressberichte 2018 SABCS - 41st Annual San Antonio Breast Cancer Symposium Press Conferences Thursday, Dec. 6 Press Conference

Program & Webcasts

Low-Dose Tamoxifen Was Safe and Effective at Reducing Recurrence and New Breast Disease for Patients With DCIS, LCIS, and ADH

Slides

Circulating Tumor Cell Count Could Help Choose Treatment for Metastatic Breast Cancer Patients

Slides

Axillary Radiotherapy and Lymph Node Surgery Yielded Comparable 10-year Outcomes for Patients with Breast Cancer

Slides

Accelerated Partial Breast Irradiation, Although Close, was Not Equivalent to Whole Breast Irradiation To Control Ipsilateral Breast Tumor Recurrence

Slides

 
Navigation überspringen
  • SABCS - 41st Annual San Antonio Breast Cancer Symposium
    • Press Conferences
      • Wednesday, Dec. 5, Press Conference 1
      • Wednesday, Dec. 5, Press Conference 2
      • Thursday, Dec. 6 Press Conference
      • Friday, Dec. 7 Press Conference
    • Schweizer Poster am SABCS
    • Interviews - Breast Cancer
    • Schweizer Expertenrunde mit einigen Highlights vom SABCS:
    • Round Table mit Brustkrebs Deutschland e.V.
    • General Sessions
  • American Society of Hematology (ASH) 60th Annual Meeting and Exposition
  • Cancer Academy: Sarkome, Früherkennung, Diagnose und Behandlung
  • ESMO 2018 Congress
  • Cancer Academy - Blut- und Lymphdrüsenkrebs
  • Comprehensive Cancer Center Zürich: Third Zurich Immuno-Oncology Symposium
  • 20th World Congress on Gastrointestinal Cancer (WCGIC 2018)
  • 23rd Congress of EHA
  • ESMO Preceptorship on Colorectal Cancer 2018
  • SENOLOGIE update 2018
  • Cancer Academy - Darmkrebs
  • AACR Annual Meeting 2018, April 14-18,
  • ELCC 2018 (European Lung Cancer Congress)
  • 11th European Breast Cancer Conference (EBCC-11)
  • St. Gallen International Gastrointestinal Cancer Conference Primary Therapy of Early GI Cancers -
  • Cancer Academy - Prostatakrebs
  • Promoting Self-efficacy with Digital Tools
 

    News

  • Alunbrig® (brigatinib) ist nun in der Erstlinientherapie und Zweit-linientherapie nach Crizotinib bei ALK+ NSCLC Patienten Kassenzulässig

    09-12-2021 11:08
    Weiterlesen ...

  • Keep an eye on:

    06-12-2021 09:19
    • ATI-450 –  pancreatic cancer.
    • darolutamide – metastatic hormone sensitive prostate cancer.
    • mirvetuximab soravtansine – in ovarian cancer.
    • KB-0742 – in MYC-amplified solid tumors.
    • zandelisib – in relapsed/refractory follicular lymphoma.
    • OP-1250 – in ≥4-line ER+/HER2-negative breast cancer.

  • November 23, 2021: Trodelvy® (sacituzumab govitecan) Granted European Commission Marketing Authorization for Treatment of mTNBC in 2nd-Line

    01-12-2021 11:22
    Weiterlesen ...

  • Miklos Pless ist neuer Präsident der Schweizerischen Arbeitsgemeinschaft für Klinische Krebsforschung (SAKK)  

    19-11-2021 10:50
    Weiterlesen ...

  • Im vergangenen Jahr investierten die Stiftung Krebsforschung Schweiz (KFS), die Krebsliga Schweiz (KLS) und die kantonalen und regionalen Krebsligen insgesamt 24,3 Mio. Franken in die Krebsforschung.

    27-09-2021 13:37
    Weiterlesen ...

  • Zulassung eines Arzneimittels mit neuem Wirkstoff: Pemazyre®, Tabletten (Pemigatinibum) - Autorisation d’un médicament contenant un nouveau principe actif: Pemazyre®, comprimés (pemigatinibum)

    09-08-2021 13:50
    Weiterlesen ...

  • Zulassung eines Arzneimittels mit neuem Wirkstoff: Clofara, Konzentrat zur Herstellung einer Infusionslösung - Autorisation d’un médicament contenant un nouveau principe actif: Clofara, solution à diluer pour perfusion

    09-08-2021 13:43
    Weiterlesen ...

  • Zulassung eines Arzneimittels mit neuem Wirkstoff: Inrebic®, Hartkapseln (Fedratinibum) - Autorisation d’un médicament contenant un nouveau principe actif: Inrebic®, gélules (fedratinibum)

    09-08-2021 13:33
    Weiterlesen ...

  • LONSURF® approved & reimbursed in 3L mGC

    02-08-2021 06:00

    Compendium (d) Compendium (f)

Newsletter

Ja  Nein 
Neu laden
Bitte geben Sie den Schriftzug ein!

Impressum

Oncoletter wird über nicht öffentlich zugängliche Werbung für Medizinalpersonen finanziert. Oncoletter finanziert sich zudem mit von Kongressorganisatoren beauftragten Aufnahmen ganzer Kongresse oder Symposien. Weitere Finanzierungsquellen werden bei den jeweiligen Berichten aufgeführt. Die Inhalte der Website von Oncoletter sind strikt redaktionell und widerspiegeln die Meinungen und Ansichten der Autoren.

Dienstleistungen

  • Livecasts
  • Kongress-Berichte
  • Journal-Review
  • Interviews
  • Videos

Kontakt

Oncoletter
DR. MED. THOMAS FERBER
POSTFACH 412
CH-8201 SCHAFFHAUSEN

Mail: info[@]oncoletter.ch